WO2016008442A1 - 含有11种甘油三酯的薏苡仁油、制剂及其应用 - Google Patents

含有11种甘油三酯的薏苡仁油、制剂及其应用 Download PDF

Info

Publication number
WO2016008442A1
WO2016008442A1 PCT/CN2015/084297 CN2015084297W WO2016008442A1 WO 2016008442 A1 WO2016008442 A1 WO 2016008442A1 CN 2015084297 W CN2015084297 W CN 2015084297W WO 2016008442 A1 WO2016008442 A1 WO 2016008442A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
coix seed
oil
seed oil
glyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/084297
Other languages
English (en)
French (fr)
Inventor
李大鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Kanglaite Group Co Ltd
Original Assignee
Zhejiang Kanglaite Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Kanglaite Group Co Ltd filed Critical Zhejiang Kanglaite Group Co Ltd
Priority to AU2015291531A priority Critical patent/AU2015291531B2/en
Priority to NZ726575A priority patent/NZ726575A/en
Priority to US15/324,873 priority patent/US10314878B2/en
Priority to EA201790119A priority patent/EA033647B1/ru
Priority to CN201580016352.9A priority patent/CN106413702B/zh
Priority to CA2954796A priority patent/CA2954796C/en
Priority to JP2017522710A priority patent/JP6473811B2/ja
Priority to SG11201700123UA priority patent/SG11201700123UA/en
Priority to EP15821404.9A priority patent/EP3170496A4/en
Priority to KR1020177001432A priority patent/KR101919386B1/ko
Priority to AP2017009707A priority patent/AP2017009707A0/en
Publication of WO2016008442A1 publication Critical patent/WO2016008442A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B1/00—Production of fats or fatty oils from raw materials
    • C11B1/10—Production of fats or fatty oils from raw materials by extracting
    • C11B1/104—Production of fats or fatty oils from raw materials by extracting using super critical gases or vapours
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B3/00—Refining fats or fatty oils
    • C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B3/00—Refining fats or fatty oils
    • C11B3/006—Refining fats or fatty oils by extraction
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B3/00—Refining fats or fatty oils
    • C11B3/008—Refining fats or fatty oils by filtration, e.g. including ultra filtration, dialysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Definitions

  • the invention relates to the field of pharmacy, in particular to a coix seed oil, a preparation, a preparation method thereof and application thereof in preparing an antitumor drug.
  • Coix seed is a mature dry seed of Coix lacryma-jobi L.var ma-yuen (Roman.) Stapf. It is a diuretic drug for a long time. Modern research has found that Coix seed has pharmacological effects such as analgesic, anti-inflammatory, immune regulation, anti-ulcer, hypolipidemic and weight loss. In recent years, domestic and foreign scholars have studied the chemical constituents of Coix seed by TLC, HPLC, GC and other methods, and found that it contains a variety of active ingredients, including coix seed esters, triglycerides, fatty acids, lactams, Compounds such as barley lactones, sugars, sterols, and triterpenoids.
  • active ingredients including coix seed esters, triglycerides, fatty acids, lactams, Compounds such as barley lactones, sugars, sterols, and triterpenoids.
  • esters are the first to be found to have anti-tumor activity, and are also the most reported chemical components.
  • Kanglaite injection which is currently used as an active ingredient in Chinese herbal medicine, has been widely used, its use of coix seed oil is complicated, and contains triglyceride and diglyceride in addition to triglyceride. And fatty acid esters, etc., which will inevitably pose great challenges to quality control and clinical drug safety in the actual production process.
  • the invention uses the hazelnut powder as a raw material, adopts the steps of supercritical carbon dioxide extraction, alkalization, neutral alumina and kaolin purification to obtain an effective part of coix seed oil; by separating and identifying the active components thereof, it is determined.
  • the composition is mainly composed of eight kinds of triglyceride components; furtherly, the physical and chemical constants are detected, and the optimal acid value, iodine value, saponification value, refractive index and relative density are determined.
  • the use of the herb of the present invention for the determination of the composition and composition of the coix seed oil ensures the quality stability between the batches in the industrial production, and also avoids the toxic side reaction caused by the complicated composition of the coix seed oil.
  • the object of the present invention is to provide a coix seed oil extracted from coix seed, which is characterized in that the coix seed oil contains 11 kinds of triglyceride components in the following mass percentage: linoleic acid glyceride 4.87 to 6.99.
  • the mass percentage of the above 11 triglyceride components is: linoleic acid glyceride 5.47-6.69%, 1-oleic acid-2,3-dilinoleic acid glyceride 14.63 to 17.88%, 1-palm Acid-2,3-dilinoleic acid glyceride 5.9 ⁇ 7.21%, 1,3-dioleic acid-2-linoleic acid glyceride 14.88 ⁇ 18.19%, 1-palmitate-2-linoleic acid -3- Oleic acid glyceride 11.55 ⁇ 14.11%, 1,3-dipalmitate-2-linoleic acid triglyceride 2.57 ⁇ 3.14%, triolein glyceride 16.25 ⁇ 19.86%, 1-palmitic acid-2,3-di Oleic acid glyceride 9.07 ⁇ 11.08%, 1-oleic acid-2-linoleic acid-3-stearic acid glyceryl ester 1.54 ⁇ 1.8
  • the mass percentage of the above-mentioned 11 kinds of triglyceride components is: glyceryl triliner 5.96 to 6.20%, glycerol 1-oleic acid-2,3-dilinoleate 15.93 to 16.58%, 1- Palmitic acid-2,3-dilinoleic acid glyceride 6.43 ⁇ 6.69%, 1,3-dioleic acid-2-linoleic acid glyceride 16.20 ⁇ 16.87%, 1-palmitate-2-linoleic acid-3 - oleic acid glyceride 12.57 to 13.09%, 1,3-dipalmitic acid-2-linoleic acid triglyceride 2.79 to 2.91%, triolein glyceride 17.69 to 18.42%, 1-palmitic acid-2,3- Diolein glyceride 9.87 ⁇ 10.27%, 1-oleic acid-2-linoleic acid-3-stearic acid glyceryl ester 1.68
  • the above content refers to the mass percentage of the triglyceride compound in the coix seed oil, and the coix seed oil prepared by the method of the invention is used as a raw material, and 11 triglyceride monomer compounds are obtained by preparative chromatography, and weighed. Calculated. It can also be derived according to conventional analytical methods in the art.
  • the physicochemical constant of the eucalyptus oil is determined by the fat oil: a relative density of 0.917 to 0.920 at 20 ° C, a refractive index of 1.471 to 1.474 at 20 ° C, an acid value of ⁇ 0.2, an iodine value of 102 to 106, and a saponification value of 188 to 195;
  • the coix seed oil of the present invention is obtained by the following method:
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 20 mesh to 60 mesh, extracted by supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater and the extraction kettle are heated by the jacketed circulating hot water.
  • Refining Take the coix seed oil obtained by supercritical CO 2 extraction, add 55% of petroleum oil with 605% C to 90 ° C oil weight, and add 2% NaOH solution with oil weight 36% to 56% according to the acid value, stir for 10 min. After standing for 18 to 24 hours, the lower layer of soap was removed, and the upper layer was washed with purified water, and after standing for 18 to 24 hours, the lower layer of wastewater was removed, and the upper layer was taken for the second water washing, and after standing for 40 to 50 hours, the lower layer of wastewater was removed. Take the upper layer and add 70% ⁇ 90% acetone to break the emulsion.
  • the lower layer of wastewater is removed;
  • the upper layer of oil is heated under reduced pressure and dried under reduced pressure, and then 8% to 12% of activated neutral alumina is added, stirred, placed in a cold place, filtered, and the filtered oil is passed through 160 ⁇ 170 ° C decompression dry heat sterilization for 1 ⁇ 2h, after cooling, filtered through a 0.2 ⁇ m microporous membrane , packaged in a 500ml glass infusion bottle, sealed, that is;
  • the refining step is:
  • the coix seed oil obtained by supercritical CO 2 extraction is added with petroleum oil of 55% by weight of 60 ° C to 90 ° C, and then added with 2% NaOH solution with oil weight of 36% to 56% according to the acid value, and stirred for 10 min, then static. After 20h, the lower layer of soap was removed, and the upper layer was washed with purified water. After standing for 22 hours, the lower layer of wastewater was removed. The upper layer was taken for the second water washing. After standing for 46 hours, the lower layer of wastewater was removed. The upper layer was added with oil weight of 70%.
  • the coix seed oil of the invention is a pale yellow clear liquid with slight gas and mild taste; it is very soluble in petroleum ether or chloroform, soluble in acetone, slightly soluble in ethanol, and insoluble in water.
  • the coix seed oil prepared according to the method of the present invention is tested according to an appendix method of the Chinese Pharmacopoeia 2010 edition, and the physical and chemical constants thereof are: relative density of 0.917 to 0.920 at 20 ° C, and refractive index of 1.471 to 1.474 at 20 ° C, acid The value is ⁇ 0.2, the iodine value is 102 to 106, and the saponification value is 188 to 195.
  • the acid value in the pharmacopoeia refers to the weight (mg) of potassium hydroxide required to neutralize the free fatty acid contained in 1 gram of fat, fatty oil or the like. In the quality study of oil and fat products, the acid value is an important evaluation index.
  • the acid value is less than 0.2, that is, the purification process by supercritical extraction parameters and alkalization in the preparation process.
  • the prepared hazelnut oil has the following advantages: on the one hand, the free fatty acid content as an impurity is extremely low, and the finished product quality is good; on the other hand, a large amount of active components of diglyceride and triglyceride are enriched, and the purity is high. And wherein the diglyceride and triglyceride components are clear in type and stable in content.
  • the preparation method of the invention has high yield, Low cost, stable product, suitable for industrial production, safe and controllable.
  • the pharmaceutically acceptable carrier includes conventional diluents, excipients, fillers, emulsifiers, binders, lubricants, absorption enhancers, surfactants, disintegrants, lubricants or An antioxidant, if necessary, a flavoring agent, a sweetener, a preservative or a coloring agent.
  • the pharmaceutically acceptable carrier may be selected from the group consisting of: mannitol, sorbitol, sodium metabisulfite, sodium hydrogen sulfite, sodium thiosulfate, cysteine hydrochloride, thioglycolic acid, methionine, soybean phospholipid, vitamin C, vitamin E , EDTA disodium, EDTA calcium sodium, monovalent alkali metal carbonate, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, hydroxybenzene Ethyl ester solution, benzoic acid, potassium sorbate, chlorhexidine acetate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and Derivatives, alginate, gelatin, polyvin
  • the pharmaceutical preparation may be an oral solid preparation, an oral liquid preparation or an injection.
  • the oral solid preparation is selected from the group consisting of a capsule, a tablet, a dropping pill, a granule, and a concentrated pill;
  • the oral liquid preparation is selected from an aqueous or oily suspension, a solution, an emulsion, a syrup or an elixir, or It is a dry product which can be formulated with water or other suitable carrier before use;
  • the injection is selected from one of a nanosuspension, a liposome, an emulsion, a lyophilized powder injection and an aqueous injection.
  • the injection comprises the following components: 50-350 g of the coix seed oil of the invention, 10-40 g of soybean phospholipid for injection or soybean lecithin for injection, glycerol for injection or 15-50 g of glycerin for injection, and water for injection is added. 1000ml.
  • Another name is the coix seed oil, the oil ester and the water phase are separately heated to 60-70 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the emulsifier homogenizer low pressure is 5 to 12 MPa, and the high pressure is 25 to 50 MPa. Recycling homogenization 3 to 6 times, to 2 ⁇ m or less, the particles should be not less than 95%, and particles above 5 ⁇ m should not be detected. If necessary, adjust the pH to 4.8 to 8.5, preferably 6.8 to 7, preferably 6.8 with NaOH or HCl. ;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter cartridge of 3 ⁇ m or less, sterilized by nitrogen filling, and cooled.
  • the capsule comprises the following components: 200 to 800 g of coix seed oil, 0.20 to 0.60 g of an antioxidant and/or an emulsifier, and 1000 capsules.
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and preservative according to the weight ratio of 1:0.6 ⁇ 1.2:0.3 ⁇ 0.8:0.0001 ⁇ 0.01; sequentially add glycerin, purified water and preservative (selected from 10% hydroxybenzene) Ethyl ester solution, one of benzoic acid, potassium sorbate and chlorhexidine acetate) is added to a plastic can, heated to 70 ° C ⁇ 90 ° C, then add gelatin, stir constantly, vacuum until gelatin is completely dissolved, will Glue filtration, stored at 56 ⁇ 62 ° C, spare;
  • Preparation of liquid medicine Add the formula amount of coix seed oil, antioxidant and/or emulsifier (antioxidant is vitamin E, emulsifier is Tween 80) into the batching tank, and stir constantly until it is evenly mixed;
  • antioxidant is vitamin E
  • emulsifier is Tween 80
  • Capsule Select the appropriate pellet mold according to the size of the capsule, dry it at 15 ⁇ 30°C and relative humidity less than 35%, then remove the size pellets, then wash the pellets with 95% medicinal ethanol and continue to dry. When the water content is less than 12%, the unqualified capsules are removed by visual inspection and the package is obtained.
  • the invention shows through pharmacodynamic experiments that the pharmaceutical composition and the preparation thereof have different degrees of inhibitory effects on various human tumor cell lines, and can be used as a medicine for treating tumor diseases.
  • the tumor refers to early, middle or late stage lung cancer, liver cancer, pancreatic cancer, prostate cancer, ovarian cancer or breast cancer.
  • compositions of the present invention and their formulations on antitumor are illustrated below by experimental data.
  • Cell lines PANC-1 (human pancreatic cancer cells), SKOV3 (human ovarian cancer cells), MCF-7 (human breast cancer cells), Bcap-37 (human breast cancer cells), SMMC-7721 (human liver cancer) Cells), HepG-2 (human liver cancer cells), A549 (human lung cancer cells), H460 (human lung cancer cells), the above cell lines were preserved by the Shanghai Pharmaceutical Industry Research Pharmacological Evaluation Research Center and maintained.
  • DMEM complete medium 10% newborn calf serum (GIBCO BRL), double antibody was added.
  • Trypsin purchased from Invitrogen, stored at -20 °C.
  • PBS Phosphate buffer
  • MTT (AMRESCO) solution A solution of 5 mg/ml was prepared with PBS.
  • Dissolving solution 10 ml of SDS, 5 ml of isobutanol and 0.1 ml of concentrated hydrochloric acid per 100 ml of deionized double distilled water.
  • the inhibitory effect of the sample on the above cell line was measured by the MTT method.
  • Cell culture 1 The cells were taken out from liquid nitrogen, rapidly thawed in a 37 ° C water bath, and the cells were transferred to a 10 ml sterile centrifuge tube in a sterile table to add 6 ml of the cell culture medium, and centrifuged at 1000 rpm for 5 minutes. Discard the supernatant, add 5-6 ml of cell culture medium to the pellet, pipette it to suspend it, transfer it to the cell culture flask, and place it in a 37 °C cell culture incubator.
  • PBS was used for gradient dilution to obtain diluted samples at concentrations of 10 mg/ml, 5000 ⁇ g/ml, 2500 ⁇ g/ml, 1250 ⁇ g/ml, 625 ⁇ g/ml, and 312.5 ⁇ g/ml.
  • the cells are trypsinized and washed, suspended in a medium containing 10% calf serum, counted by the trypan blue staining method, and the cell suspension is adjusted.
  • the density is 2 x 10 5 cells/ml.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 20 mesh, extracted by supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater, the extraction kettle and the separation column are heated by the jacket circulating hot water.
  • the extraction temperature and the separation temperature were respectively 40 ° C and 45 ° C, and the outlet temperatures of the first stage analytical reactor and the secondary analytical reactor were 50 ° C and 35 ° C, respectively; the liquid CO 2 flow rate was 2.5 kg according to the mass of the extracted hazelnut powder.
  • the flow rate of /h ⁇ kg is pressurized into the CO 2 preheater by the high pressure pump, becomes the fluid in the supercritical state, enters the extraction kettle, maintains the pressure 20Mpa, extracts the coix seed oil; the CO 2 fluid dissolved in the coix seed oil enters the separation Column, control separation column pressure 7Mpa, separation of coix seed oil; CO 2 gas from the separation column into the first and second stage analytical kettle, respectively, maintaining pressure of 7Mpa and 6Mpa, discard the impurities and other impurities obtained by analysis, CO 2 gas into a liquid CO 2 through a condenser, recycled, continuous extraction for 2.5h, to obtain coix seed oil;
  • Acetone demulsification after standing for 3h, remove the lower layer of waste acetone; take the upper layer of oil solution, add 5% activated neutral alumina, stir for 30min, then filter; after heating the filtrate, add 4% activated kaolin, stir After incubation at 45 ° C for 30 min, filtration; the filtrate was recovered under reduced pressure, and then purified water was added for washing. After standing for 1 h, the lower layer of wastewater was removed; the upper layer of oil was dried under reduced pressure with nitrogen, and then added with 10%. The activated neutral alumina is stirred, placed in a cold place, and filtered. The filtered oil is then sterilized by dry heat at 165 ° C for 2 h.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 30 mesh, extracted by supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater, the extraction kettle and the separation column are heated by the jacketed circulating hot water.
  • the extraction temperature and the separation temperature were respectively 35 ° C and 40 ° C, and the outlet temperatures of the first-stage analytical kettle and the secondary analytical reactor were 20 ° C and 15 ° C, respectively; the liquid CO 2 flow rate was 7.5 kg based on the mass of the extracted hazelnut powder.
  • the flow rate of /h ⁇ kg is pressurized into the CO 2 preheater by the high pressure pump, becomes the fluid in the supercritical state, enters the extraction kettle, maintains the pressure of 22Mpa, extracts the coix seed oil; the CO 2 fluid dissolved in the coix seed oil enters the separation Column, control separation column pressure 8Mpa, separation of coix seed oil; CO 2 gas from the separation column into the first and second stage analytical reactor, respectively, maintaining pressure of 6Mpa and 5Mpa, discard the moisture and other impurities obtained by analysis, CO 2 gas into a liquid CO 2 through a condenser, recycled, continuous extraction for 2h, to obtain coix seed oil;
  • Refining Take the coix seed oil extracted by supercritical CO 2 , add 55% of petroleum oil with 905% by weight of oil, and add 5% NaOH solution with 56% oil weight according to the acid value. After stirring for 10 min, let stand for 22 h. The lower layer of soap was removed, and the upper layer was washed with purified water. After standing for 20 hours, the lower layer of wastewater was removed, and the upper layer was taken for the second water washing. After standing for 48 hours, the lower layer of wastewater was removed; the upper layer was added with oil weighing 90% acetone to break the emulsion.
  • Alumina stirred, placed in a cold place, filtered, filtered oil was dried and dried at 170 ° C for 1.5 h under reduced pressure, cooled, filtered through a 0.2 ⁇ m microporous membrane, and dispensed in a 500 ml glass infusion bottle. , sealed, that is, the oil, the yield is 4.9% Determination of physico-chemical constants: 0.920,20 °C relative density at 20 °C refractive index of 1.473, an acid value of 0.19, an iodine value of 104, a saponification value of 188.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 40 mesh, extracted by supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater, the extraction kettle and the separation column are heated by the jacket circulating hot water.
  • the extraction temperature and the separation temperature were respectively 33 ° C and 39 ° C, and the outlet temperatures of the first-stage analytical kettle and the secondary analytical reactor were 30 ° C and 20 ° C, respectively; the liquid CO 2 flow rate was 5.5 kg according to the mass of the extracted hazelnut powder.
  • the flow rate of /h ⁇ kg is pressurized into the CO 2 preheater by the high pressure pump, becomes the fluid in the supercritical state, enters the extraction kettle, maintains the pressure 19Mpa, extracts the coix seed oil; the CO 2 fluid dissolved in the coix seed oil enters the separation Column, control separation column pressure 9Mpa, separation of coix seed oil; CO 2 gas from the separation column into the first and second stage analytical kettle, respectively, maintaining pressure of 5Mpa and 4Mpa, discard the water and other impurities obtained by analysis, CO 2 gas into a liquid CO 2 through a condenser, recycled, continuous extraction for 3h, to obtain coix seed oil;
  • Refining Take the coix seed oil extracted by supercritical CO 2 , add 55% of petroleum oil with 805% by weight of oil, and add 2% NaOH solution with 36% oil weight according to the acid value. After stirring for 10 min, let stand for 18 h. The lower layer of soap was removed, and the upper layer was washed with purified water. After standing for 18 hours, the lower layer of wastewater was removed, and the upper layer was taken for the second time. After standing for 42 hours, the lower layer of wastewater was removed; the upper layer was added with 75% acetone to break the emulsion.
  • the lower layer of wastewater was removed; the upper layer of oil was dried under reduced pressure with nitrogen, and then added with 11% Activated neutral alumina, stirred, placed in a cool place, filtered, filtered and then sterilized by dry heat at 160 ° C for 2 h, cooled, filtered through a 0.2 ⁇ m microporous membrane, and dispensed in 500 ml glass infusion In the bottle, the seal is obtained.
  • the rate was 4.7%; the physicochemical constant was determined to be: a relative density of 0.918 at 20 ° C, a refractive index of 1.474 at 20 ° C, an acid value of 0.15, an iodine value of 102, and a saponification value of 194.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 50 mesh, extracted by supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater, the extraction kettle and the separation column are heated by the jacket circulating hot water.
  • the extraction temperature and the separation temperature were respectively 35 ° C and 42 ° C, and the outlet temperatures of the first-stage analytical kettle and the secondary analytical reactor were 40 ° C and 30 ° C respectively; the liquid CO 2 flow rate was 4.5 kg based on the mass of the extracted hazelnut powder.
  • the flow rate of /h ⁇ kg is pressurized into the CO 2 preheater by the high pressure pump, becomes the fluid in the supercritical state, enters the extraction kettle, maintains the pressure 21Mpa, extracts the coix seed oil; the CO 2 fluid dissolved in the coix seed oil enters the separation Column, control separation column pressure 10Mpa, separation of coix seed oil; CO 2 gas from the separation column into the primary and secondary analytical reactor, respectively, maintaining pressure of 7Mpa and 5Mpa, discard the analysis of the moisture and other impurities, CO 2 gas into a liquid CO 2 through a condenser, recycled, continuous extraction for 2h, to obtain coix seed oil;
  • Alumina stirred, placed in a cold place, filtered, filtered oil was sterilized by dry heat at 162 ° C for 1 h, cooled, filtered through a 0.2 ⁇ m microporous membrane, and dispensed in a 500 ml glass infusion bottle. Sealed, that is, the coix seed oil, the yield is 4.0%; Given its physical and chemical constants: 0.920,20 °C relative density at 20 °C refractive index of 1.471, an acid value of 0.16, an iodine value of 105, a saponification value of 192.
  • Supercritical carbon dioxide extraction the coix seed is pulverized into 60 mesh, extracted by supercritical CO 2 extractor, and the coix seed powder is charged into the extraction kettle, and the CO 2 preheater, the extraction kettle and the separation column are heated by the jacket circulating hot water.
  • the extraction temperature and the separation temperature were respectively 42 ° C and 45 ° C, and the outlet temperatures of the first stage analytical reactor and the secondary analytical reactor were 35 ° C and 25 ° C, respectively; the liquid CO 2 flow rate was 6.5 kg according to the mass of the extracted hazelnut powder.
  • the flow rate of /h ⁇ kg is pressurized into the CO 2 preheater by the high pressure pump, becomes the fluid in the supercritical state, enters the extraction kettle, maintains the pressure 23Mpa, extracts the coix seed oil; the CO 2 fluid dissolved in the coix seed oil enters the separation Column, control separation column pressure 8Mpa, separation of coix seed oil; CO 2 gas from the separation column into the first and second stage analytical kettle, respectively, maintaining pressure of 6Mpa and 4Mpa, discard the moisture and other impurities obtained by analysis, CO 2 gas into a liquid CO 2 through a condenser, recycled, continuous extraction for 2.5h, to obtain coix seed oil;
  • Refining Take the coix seed oil extracted by supercritical CO 2 , add 55% of petroleum oil with 805% by weight of oil, add 4% NaOH solution with oil weight of 40% according to the acid value, stir for 10 min, and let stand for 24 h. The lower layer of soap was removed, and the upper layer was washed with purified water. After standing for 24 hours, the lower layer of wastewater was removed, and the upper layer was taken for the second water washing. After standing for 44 hours, the lower layer of wastewater was removed; and the upper layer was added with 70% acetone to break the emulsion.
  • Alumina, stirred, placed in a cold place, filtered, filtered oil was sterilized by dry heat at 165 ° C for 2 h, cooled, filtered through a 0.2 ⁇ m microporous membrane, and dispensed in a 500 ml glass infusion bottle. Sealed, that is, the coix seed oil, the yield is 4.3%;
  • the physicochemical constant was determined to be: a relative density of 0.917 at 20 ° C, a refractive index of 1.473 at 20 ° C, an acid value of 0.14, an iodine value of 103, and a saponification value of 192.
  • mobile phase A acetonitrile
  • mobile phase B acetonitrile-tetrahydrofuran (1:1)
  • Mobile phase B 0 to 27 min: 50% to 60%, 27 to 35 min: 90%, 35 to 45 min: 100%
  • Flow rate 18 mL/min
  • UV detection wavelength 208 nm
  • collected chromatographic peak fraction with retention time of 12.6 to 14.2 min concentrated under reduced pressure with a rotary evaporator under a nitrogen atmosphere, transferred to a 10 mL vial with chloroform, and dried under vacuum After drying in a box at 35 ° C for 6 h, it was filled with nitrogen gas, and the dried sample was stored in a freezer in a refrigerator to obtain tri oleic acid glyceride
  • A tri linoleic acid glyceride
  • B 1-oleic acid-2,3-dilinoleic acid glyceride
  • C 1-palmitic acid-2,3-dilinoleic acid glyceride
  • D 1, 3-Dioleic acid-2-linoleic acid glyceride
  • E 1-palmitic acid-2-linoleic acid-3-oleic acid glyceride
  • F 1,3-dipalmitate-2-linoleic acid glycerin Triester
  • G triolein
  • H 1-palmitic acid-2,3-dioleate.
  • A tri linoleic acid glyceride
  • B 1-oleic acid-2,3-dilinoleic acid glyceride
  • C 1-palmitic acid-2,3-dilinoleic acid glyceride
  • D
  • Preliminary separation was carried out by P3000A high performance liquid chromatography, mobile phase A: acetonitrile, mobile phase B: acetonitrile-tetrahydrofuran (1:1), and mobile phase B was prepared into 50 mg/mL hazelnut oil solution, each time separated.
  • the mobile phase A acetonitrile
  • mobile phase B acetonitrile-tetrahydrofuran (1:1)
  • the above crude product was prepared into a 20 mg/mL solution using mobile phase B, and the injection volume was 1.5 mL each time;
  • Superstar Benetnach TM C 18 (10 mm ⁇ 250 mm, 5 ⁇ m);
  • Gradient conditions Mobile phase B: 0 to 23 min: 50% to 60%, 32 to 43 min: 60% to 90%, 43 to 60 min: 100%; 3mL/min;
  • UV detection wavelength: 208nm collect the chromatographic peak fraction with retention time of 31.2 ⁇ 34.7min, concentrate under reduced pressure with nitrogen under the protection of nitrogen, transfer to 10mL vial with chloroform, in vacuum drying oven 35 After drying at ° C for 6 h, nitrogen was charged, and the dried sample was stored in a freezer in a refrigerator to obtain 1-palmitic acid-2,3-dilinoleic acid glyceride monomer.
  • Preliminary separation was carried out by P3000A high performance liquid chromatography, mobile phase A: acetonitrile, mobile phase B: acetonitrile-tetrahydrofuran (1:1), and mobile phase B was prepared into 50 mg/mL hazelnut oil solution, each time separated.
  • Preliminary separation was carried out by P3000A high performance liquid chromatography, mobile phase A: acetonitrile, mobile phase B: acetonitrile-tetrahydrofuran (1:1), and mobile phase B was prepared into 50 mg/mL hazelnut oil solution, each time separated.
  • Preliminary separation was carried out by P3000A high performance liquid chromatography, mobile phase A: acetonitrile, mobile phase B: acetonitrile-tetrahydrofuran (1:1), and mobile phase B was prepared into 50 mg/mL hazelnut oil solution, each time separated.
  • the mobile phase A acetonitrile
  • mobile phase B acetonitrile-tetrahydrofuran (1:1)
  • the above crude product was prepared into a 20 mg/mL solution using mobile phase B, and the injection volume was 1.5 mL each time;
  • Superstar Benetnach TM C 18 (10 mm ⁇ 250 mm, 5 ⁇ m);
  • Gradient conditions Mobile phase B: 0 to 23 min: 50% to 60%, 32 to 43 min: 60% to 90%, 43 to 60 min: 100%; flow rate: 3 mL /min; UV detection wavelength: 208nm, collect the chromatographic peak fraction with retention time of 32.9 ⁇ 35.1min, concentrate under reduced pressure with nitrogen under the protection of nitrogen, transfer to 10mL vial with chloroform, 35°C in vacuum drying oven After drying for 6 hours, nitrogen was charged, and the dried sample was stored in a freezer in a refrigerator to obtain 1-palmitic acid-2,3-dioleate.
  • the CHEETAH-HP100 high performance liquid chromatograph was used for preliminary separation.
  • the injection volume was 2 mL each time.
  • the preliminary separation was carried out by using CHEETAH-HP100 high performance liquid chromatography.
  • the preliminary separation was carried out by using CHEETAH-HP100 high performance liquid chromatography.
  • coix seed oil contains the following triglyceride components:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • Another name is the coix seed oil, the weighed oil and water are separately heated to 60 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification, the homogenizer low pressure is 6MPa, the high pressure is 30MPa, the recycling is homogeneous 4 times , the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 8.5 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following triglyceride components:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil ester and the water phase are separately heated to 70 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification, the homogenizer low pressure is 12 MPa, the high pressure is 45 MPa, and the recycling is uniform. All the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 7.1 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following triglyceride components:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil ester and the water phase are separately heated to 65 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the emulsifier homogenizer low pressure is 10 MPa
  • the high pressure is 30 MPa
  • the recirculation is homogeneous 5 All the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 4.8 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following triglyceride components:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil ester and the water phase are separately heated to 68 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the emulsifier homogenizer low pressure is 7 MPa
  • the high pressure is 35 MPa
  • the recirculation is homogeneous 3 All the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 6.8 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following triglyceride components:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and 10% hydroxyethyl ester solution according to the weight ratio of 1:1.2:0.8:0.01; add glycerin, purified water and 10% hydroxyethyl ester solution to the rubber In the tank, after heating to 70 ° C, add gelatin and stir constantly, vacuum until the gelatin is completely dissolved, filter the glue, store at 60 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and vitamin E into the ingredient tank, and stir constantly until it is evenly mixed;
  • Capsule Select the appropriate pellets according to the size of the capsules, and then dry at 18 °C and relative humidity ⁇ 35%. After the pellets are dried, the pellets are removed, and the pellets are washed with 95% medicinal ethanol. The amount of water is less than 12%, and the unqualified capsules are removed by visual inspection.
  • coix seed oil contains the following triglyceride components:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and benzoic acid at a weight ratio of 1:1.2:0.8:0.01; add glycerin, purified water and benzoic acid to the gelatin tank in turn, heat to 90 °C, then Add gelatin and stir constantly, vacuum until the gelatin is completely dissolved, filter the glue, store at 56 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and Tween 80 into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule Select the appropriate pellet mold according to the size of the capsule, and then dry it at 26 ° C and relative humidity ⁇ 35%, then remove the size pellets, and then wash the pellets with 95% medicinal ethanol, then continue to dry to contain The amount of water is less than 12%, and the unqualified capsules are removed by visual inspection.
  • coix seed oil contains the following triglyceride components:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and potassium sorbate according to the weight ratio of 1:0.9:0.6:0.005; add glycerin, purified water and potassium sorbate to the gelatin tank in turn, and heat to 80 °C. Then add gelatin and stir constantly, vacuum, until the gelatin is completely dissolved, filter the glue, store at 62 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and vitamin E into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule select the appropriate pellet mold according to the size of the capsule, and then dry it at 28 ° C and relative humidity ⁇ 35%, then remove the size pellets, then wash the pellets with 95% medicinal ethanol, and continue to dry until The amount of water is less than 12%, and the unqualified capsules are removed by visual inspection.
  • coix seed oil contains the following triglyceride components:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and chlorhexidine acetate according to the weight ratio of 1:1.0:0.5:0.008; add glycerin, purified water and chlorhexidine acetate to the gelatin tank in turn, and heat to 85 After °C, add gelatin and stir constantly. Vacuum the gel until the gelatin is completely dissolved, filter the glue, store at 56 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and Tween 80 into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule select the appropriate pellet mold according to the size of the capsule, dry it at 30 ° C, relative humidity ⁇ 35%, and then remove the size pellets, then wash the pellets with 95% medicinal ethanol, and continue to dry until The amount of water is less than 12%, and the unqualified capsules are removed by visual inspection.
  • coix seed oil contains the following triglyceride components:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • the coix seed oil the oil and the water phase are separately heated to 60 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the homogenizer has a low pressure of 7 MPa, a high pressure of 26 MPa, and a recycling homogenization of 5 times.
  • the particles below 2 ⁇ m should be not less than 95%, particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 6.8 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following triglyceride components:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil and the water phase are separately heated to 70 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the homogenizer low pressure is 11 MPa
  • the high pressure is 48 MPa
  • the recycling is homogenized 6 times.
  • the particles below 2 ⁇ m should be not less than 95%
  • particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 7.5 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following triglyceride components:
  • soy lecithin for injection add appropriate amount of water for injection, disperse it to a block-free and granular solid with a high-shear dispersing emulsifier, add glycerin for injection, which is weighed according to the formula, and add water for injection. To the specified amount, stir evenly;
  • coix seed oil the oil and the water phase are separately heated to 65 ° C, and then placed in a high-pressure homogenizer for high-pressure emulsification.
  • the emulsifier homogenizer low pressure is 8 MPa
  • the high pressure is 40 MPa
  • the recirculation is homogeneous 4 times.
  • the particles below 2 ⁇ m should be not less than 95%
  • particles above 5 ⁇ m should not be detected, if necessary, adjust the pH to 6.5 with NaOH or HCl;
  • the uniform emulsion nitrogen gas is pressurized and filtered through a microporous filter filter of ⁇ 3 ⁇ m, sterilized by nitrogen filling, and cooled.
  • coix seed oil contains the following triglyceride components:
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and 10% hydroxyethyl ester solution according to the weight ratio of 1:1.2:0.8:0.01; add glycerin, purified water and 10% hydroxyethyl ester solution to the rubber In the tank, after heating to 70 ° C, add gelatin and stir constantly, vacuum until the gelatin is completely dissolved, filter the glue, store at 59 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and vitamin E into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule select the appropriate pellet mold according to the size of the capsule, dry it at 16 °C and relative humidity ⁇ 35%, then remove the size pellets, then wash the pellets with 95% medicinal ethanol, and continue to dry until The amount of water is less than 12%, and the unqualified capsules are removed by visual inspection.
  • coix seed oil contains the following triglyceride components:
  • 1,3-dioleic acid-2-linoleic acid glyceride 18.50%
  • Preparation of glue weigh the appropriate amount of gelatin, purified water, glycerin and benzoic acid according to the weight ratio of 1:1.2:0.8:0.01; Glycerin, purified water and benzoic acid were added to the gelatin tank, heated to 90 ° C, and then gelatin was added to stir and vacuum until the gelatin was completely dissolved. The glue was filtered and stored at 60 ° C for use;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and Tween 80 into the ingredient tank, and stir constantly until it is evenly mixed;
  • Pressure capsule Select the appropriate pellet mold according to the size of the capsule, and then dry it at 26 ° C and relative humidity ⁇ 35%, then remove the size pellets, and then wash the pellets with 95% medicinal ethanol, then continue to dry to contain The amount of water is less than 12%, and the unqualified capsules are removed by visual inspection.
  • coix seed oil contains the following triglyceride components:
  • 1,3-dioleic acid-2-linoleic acid glyceride 15.01%
  • Preparation of glue Weigh the appropriate amount of gelatin, purified water, glycerin and potassium sorbate according to the weight ratio of 1:0.9:0.6:0.005; add glycerin, purified water and potassium sorbate to the gelatin tank in turn, and heat to 80 °C. Then add gelatin and stir constantly, vacuum, until the gelatin is completely dissolved, filter the glue, store at 62 ° C, and set aside;
  • Preparation of liquid medicine Add the formula amount of coix seed oil and vitamin E into the ingredient tank, and stir constantly until it is evenly mixed;
  • Capsule Select the appropriate pellets according to the size of the capsules, and then dry at 20 °C and relative humidity ⁇ 35%, then remove the pellets, then wash the pellets with 95% medicinal ethanol, and continue to dry until The amount of water is less than 12%, and the unqualified capsules are removed by visual inspection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种从薏苡仁中提取的含有11种甘油三酯的薏苡仁油、制剂及其应用。具体的，该薏苡仁油中含有下述11种甘油三酯类成分（按质量百分比计）：三亚油酸甘油酯（4.87-6.99%），1-油酸-2,3-二亚油酸甘油酯（13.00-18.69%），1-棕榈酸-2,3-二亚油酸甘油酯（5.25-7.54%），1,3-二油酸-2-亚油酸甘油酯（13.23-19.02%），1-棕榈酸-2-亚油酸-3-油酸甘油酯（10.26-14.75%），1,3-二棕榈酸-2-亚油酸甘油酯（2.28-3.28%），三油酸甘油酯（14.44-20.76%），1-棕榈酸-2,3-二油酸甘油酯（8.06-11.58%），1-油酸-2-亚油酸-3-硬脂酸甘油酯（1.37～1.97％），1,3-二棕榈酸-2-油酸甘油酯（1.52～2.19％）和1,2-二油酸-3-硬脂酸甘油酯（1.29～1.86％）。所述薏苡仁油能在制备抗肿瘤的药物中应用。

Description

含有11种甘油三酯的薏苡仁油、制剂及其应用 技术领域
本发明涉及药学领域，具体而言，本发明涉及一种薏苡仁油、制剂、制备方法及其在制备抗肿瘤药物中的应用。
背景技术
薏苡仁是禾本科薏苡属植物薏苡Coix lacryma-jobi L.var ma-yuen(Roman.)Stapf的成熟干燥种仁，为利水渗湿药，很久以来为药食两用品种。现代研究发现薏苡仁具有镇痛抗炎、免疫调节、抗溃疡、降血脂和减肥等药理作用。近年来，国内外学者通过TLC、HPLC、GC等方法对薏苡仁的化学成分进行了研究，发现其含有多种活性成分，主要包括薏苡仁酯、甘油三酯类、脂肪酸类、内酰胺类、薏苡仁内酯、糖类、甾醇类、三萜类等化合物。其中，酯类是首先被发现的具有抗肿瘤活性的成分，也是报道最多最受关注的化学成分。虽然目前在中国临床上以薏苡仁油为有效成分的康莱特注射剂已得到普遍应用，但其使用的薏苡仁油成分较复杂，除含有甘油三酯成分外，还含有甘油一酯、甘油二酯以及脂肪酸酯等，这必然会使实际生产过程中的质量控制和临床用药安全面临很大的挑战。
本发明以薏苡仁粉为原料，采用超临界二氧化碳萃取、碱化、中性氧化铝和高岭土纯化等步骤，得到了一种薏苡仁油有效部位；通过对其活性成分的分离与鉴定，确定了其组成主要为八种甘油三酯成分；并进一步对其进行理化常数的检测，确定了其最优酸值、碘值、皂化值、折光率和相对密度等。采用本发明所述薏苡仁油用药，成分及组成确定，保证了工业生产中各批次间的质量稳定性，也避免了因直接采用薏苡仁油入药而成分复杂不清导致的毒副反应。
发明内容
本发明的目的在于提供一种从薏苡仁中提取的薏苡仁油，其特征在于：该薏苡仁油中含有如下质量百分含量的11种甘油三酯类成分：三亚油酸甘油酯4.87～6.99％、1-油酸-2,3-二亚油酸甘油酯13.00～18.69％、1-棕榈酸-2,3-二亚油酸甘油酯5.25～7.54％、1,3-二油酸-2-亚油酸甘油酯13.23～19.02％、1-棕榈酸-2-亚油酸-3-油酸甘油酯10.26～14.75％、1,3-二棕榈酸-2-亚油酸甘油三酯2.28～3.28％、三油酸甘油酯14.44～20.76％、1-棕榈酸-2,3-二油酸甘油酯8.06～11.58％、1-油酸-2-亚油酸-3-硬脂酸甘油酯1.37～1.97％、1,3-二棕榈酸-2-油酸甘油酯1.52～2.19％和1,2-二油酸-3-硬脂酸甘油酯1.29～1.86％。
优选的，上述11种甘油三酯成分的质量百分含量为：三亚油酸甘油酯5.47-6.69％、1-油酸-2,3-二亚油酸甘油酯14.63～17.88％、1-棕榈酸-2,3-二亚油酸甘油酯5.9～7.21％、1,3-二油酸-2-亚油酸甘油酯14.88～18.19％、1-棕榈酸-2-亚油酸-3-油酸甘油酯11.55～14.11％、1,3-二棕榈酸-2-亚油酸甘油三酯2.57～3.14％、三油酸甘油酯16.25～19.86％、1-棕榈酸-2,3-二油酸甘油酯9.07～11.08％、1-油酸-2-亚油酸-3-硬脂酸甘油酯1.54～1.88％、1,3-二棕榈酸-2-油酸甘油酯1.71～2.09％和1,2-二油酸-3-硬脂酸甘油酯1.45～1.78％；
更优选的，上述11种甘油三酯成分的质量百分含量为：三亚油酸甘油酯5.96～6.20％、1-油酸-2,3-二亚油酸甘油酯15.93～16.58％、1-棕榈酸-2,3-二亚油酸甘油酯6.43～6.69％、1,3-二油酸-2-亚油酸甘油酯16.20～16.87％、1-棕榈酸-2-亚油酸-3-油酸甘油酯12.57～13.09％、1,3-二棕榈酸-2-亚油酸甘油三酯2.79～2.91％、三油酸甘油酯17.69～18.42％、1-棕榈酸-2,3-二油酸甘油酯9.87～10.27％、1-油酸-2-亚油酸-3-硬脂酸甘油酯1.68～1.74％、1,3-二棕榈酸-2-油酸甘油酯1.86～1.94％和1,2-二油酸-3-硬脂酸甘油酯1.58～1.65％。
上述含量均指甘油三酯化合物在薏苡仁油中的质量百分含量，以本发明所述方法制备得到的薏苡仁油为原料，经过制备色谱分离得到11个甘油三酯单体化合物，称重、计算而得。也可根据本领域常规分析方法得出。
其中，所述薏苡仁油按脂肪油检测理化常数为：20℃时相对密度0.917～0.920，20℃时折光率1.471～1.474，酸值<0.2，碘值102～106，皂化值188～195；
本发明所述的薏苡仁油是通过如下方法获得的：
超临界二氧化碳萃取：取薏苡仁粉碎成20目～60目，采用超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到33～45℃和30～45℃，保持一级解析釜和二级解析釜出口温度分别为20～50℃和15～35℃；液态CO2流量按所萃取薏苡仁粉末质量计，以2.5kg/h·kg～7.5kg/h·kg的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力19～23Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力7～10Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为5～7Mpa和4～6Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2～3h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量55％的60℃～90℃石油醚，再根据酸值，加入油重36％～56％的2％NaOH溶液，搅拌10min后，静置18～24h后，除去下层皂脚，取上层用纯化水进行水洗，静置18～24h后，除去下层废水，取上层进行第二次水洗，静置40～50h后，除去下层废水；取上层加入油重70％～90％丙酮破乳，静置2～4h后，除去下层废丙酮；取上层油溶液，加入3％～8％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入2％～6％经活化的高岭土，搅拌，在40～50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1～2h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加8％～12％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经160～170℃减压干热灭菌1～2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得；
优选地，所述精制步骤为：
取超临界CO2萃取得到的薏苡仁油，加入油重量55％的60℃～90℃石油醚，再根据酸值，加入油重36％～56％的2％NaOH溶液，搅拌10min后，静置20h后，除去下层皂脚，取上层用纯化水进行水洗，静置22h后，除去下层废水，取上层进行第二次水洗，静置46h后，除去下层废水；取上层加入油重70％～90％丙酮破乳，静置3h后，除去下层废丙酮；取上层油溶液，加入5％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入4％经活化的高岭土，搅拌，在40～50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加10％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经160～170℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得。
本发明所述薏苡仁油为淡黄色的澄明液体，气微、味淡；其在石油醚或三氯甲烷中极易溶解，在丙酮中易溶、在乙醇中微溶，在水中不溶。
按照本发明所述方法制备得到的薏苡仁油，依照中国药典2010年版一部附录方法进行检测，其理化常数均为：20℃时相对密度0.917～0.920，20℃时折光率1.471～1.474，酸值<0.2，碘值102～106，皂化值188～195。其中，药典所述酸值系指中和脂肪、脂肪油或其他类似物质1克中含有的游离脂肪酸所需氢氧化钾的重量(毫克数)。在油脂类产品的质量研究中，酸值是一个重要评价指标，就本申请所述薏苡仁油而言，其酸值均小于0.2，即通过对制备工艺中超临界萃取参数和碱化等纯化工艺的优化，制备得到的薏苡仁油具有如下优点：一方面作为杂质的游离脂肪酸含量极低，成品质量较好；另一方面富集了大量甘油二酯、甘油三酯类活性成分，纯度较高，并且其中甘油二酯和甘油三酯类成分种类明确、含量稳定。除此之外，其它理化常数，如皂化值、碘值等，多批次样品测得该值变化范围均较小，进一步说明本发明所述薏苡仁油的质量稳定、临床用药更安全。本发明所述制备方法收率高、 成本低、产品稳定，适于工业化生产，安全可控。
本发明的又一目的在于提供一种含有薏苡仁油的药物制剂，具体包括本发明所述薏苡仁油及一种或几种药学上可接受的载体。
其中，所述药学上可接受的载体包括药学领域常规的稀释剂、赋形剂、填充剂、乳化剂、粘合剂、润滑剂、吸收促进剂、表面活性剂、崩解剂、润滑剂或抗氧化剂，必要时还可以加入香味剂、甜味剂、防腐剂或着色剂。
所述药学上可接受的载体可以选自：甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、大豆磷脂、维生素C、维生素E、EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、羟苯乙酯溶液、苯甲酸、山梨酸钾、醋酸氯己定、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙或硬脂酸镁。
所述药物制剂可以是口服固体制剂、口服液体制剂或注射剂。
优选的，
所述口服固体制剂选自胶囊剂、片剂、滴丸、颗粒剂、浓缩丸中的一种；所述口服液体制剂选自水性或油性悬浮液、溶液、乳剂、糖浆剂或酏剂，或是一种在使用前可用水或其它适宜的载体复配的干燥产品；所述注射剂选自纳米混悬剂、脂质体、乳剂、冻干粉针剂和水针剂中的一种。
更优选的，
所述注射剂包括如下成分：本发明所述薏苡仁油50～350g，注射用大豆磷脂或可供注射用大豆磷脂10～40g，注射用甘油或可供注射用甘油15～50g，注射用水加至1000ml。
其可通过如下方法制备：
称取处方配制量的注射用大豆磷脂或可供注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油或可供注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油酯与水相分别加热至60～70℃后，置高压均质机进行高压乳化，乳化时均质机低压为5～12MPa，高压为25～50MPa，再循环均质3～6遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至4.8～8.5，优选6.8～7，最优选为6.8；
将制得均匀乳剂氮气加压通过小于等于3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
所述胶囊剂包括如下成分：薏苡仁油200～800g，抗氧化剂和/或乳化剂0.20～0.60g，制成1000粒。
其可通过如下方法制备：
胶液配制：按重量比为1∶0.6～1.2∶0.3～0.8∶0.0001～0.01称取适量明胶、纯化水、甘油和防腐剂；依次将甘油、纯化水、防腐剂(选自10％羟苯乙酯溶液、苯甲酸、山梨酸钾和醋酸氯己定中的一种)加入化胶罐内，加热至70℃～90℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在56～62℃下存放，备用；
药液配制：将配方量的薏苡仁油、抗氧化剂和/或乳化剂(抗氧化剂为维生素E，乳化剂为吐温80)加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在15～30℃、相对湿度小于35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得。
本发明通过药效实验表明，所述药物组合物及其制剂对多种人肿瘤细胞株均有不同程度的抑制作用，可作为治疗肿瘤疾病药物。
因此，本发明的目的还在于提供一种上述药物组合物、药物制剂在制备抗肿瘤药物中的应用。
其中，所述肿瘤是指早期、中期或晚期的肺癌、肝癌、胰腺癌、前列腺癌、卵巢癌或乳腺癌。
以下通过实验数据说明本发明所述组合物及其制剂在抗肿瘤方面的有益效果。
一、体外MTT法测定薏苡仁油及其制剂对8种人肿瘤细胞株的抑制作用
1、实验材料及配制
(1)细胞株：PANC-1(人胰腺癌细胞)、SKOV3(人卵巢癌细胞)、MCF-7(人乳腺癌细胞)、Bcap-37(人乳腺癌细胞)、SMMC-7721(人肝癌细胞)、HepG-2(人肝癌细胞)、A549(人肺癌细胞)、H460(人肺癌细胞)，上述细胞株由上海医药工业研究药理评价研究中心保存，传代维持。
(2)DMEM完全培养基：添加10％新生牛血清(GIBCO BRL)、双抗。
(3)0.25％胰蛋白酶溶液(Trypsin)：购自Invitrogen公司，-20℃保存。
(4)磷酸缓冲液(PBS)：NaCl 8g，KCl 0.2g，Na2HPO4 1.15g，KH2PO4 0.2g，溶于1L双蒸水，121℃高压消毒20min，4℃保存。
(5)MTT(AMRESCO)溶液：用PBS配成5mg/ml溶液。
(6)溶解液：每100ml去离子双蒸水含SDS 10g，异丁醇5ml，浓盐酸0.1ml。
2、实验方法
样品对上述细胞株的抑制作用通过MTT法测得。
具体步骤如下：
(1)细胞培养：①将细胞从液氮中取出，在37℃水浴中迅速解冻，细胞在无菌操作台中移入10ml无菌离心管中加6ml细胞培养基，1000转/分钟离心5分钟。弃去上清液，沉淀中加入5～6ml细胞培养基，滴管吹打使其悬浮后移入细胞培养瓶中，置37℃细胞培养箱内。②次日，自培养箱中取出细胞，弃去细胞瓶中细胞培养基，加入5～6ml细胞培养基，置37℃细胞培养箱内。③隔日，自培养箱中取出细胞，弃去细胞瓶中细胞培养基，加入PBS(pH7.4)2～3ml晃动清洗，倒掉PBS溶液后再重复一次清洗。在培养瓶中加入3～5滴0.25％胰蛋白酶溶液晃动均匀，加盖置于37℃细胞培养箱内3分钟左右，于显微镜下观察发现细胞自培养瓶壁上脱离，加细胞培养基2ml，滴管吹打使细胞完全脱离瓶壁后，分别移入2个干净培养瓶中，加入细胞培养基5～6ml吹打均匀，置于37℃细胞培养箱内。④隔日，重复③步骤。在整个培养过程中，贴壁细胞不允许生长过密，悬浮细胞始终保持对数生长期。(2)样品及对照品制备：称取适量薏苡仁油样品溶解于DMSO中，得到浓度为10mg/ml的溶液。再用PBS作梯度稀释，得到浓度10mg/ml、5000μg/ml、2500μg/ml、1250μg/ml、625μg/ml、312.5μg/ml的稀释样品。
(3)将稀释好的样品加入平底96孔板中，每孔10μl，每点作两个平行测试。将DMSO相应作梯度稀释后加入板中，作为对照。
(4)取处于对数生长期的细胞，细胞经胰酶消化并洗涤后悬浮于含10％小牛血清的培养基中，经苔盼蓝染色排除法计活细胞数，并调节细胞悬浮液密度至2×105个细胞/ml。
(5)将加入细胞的平底96孔板在37℃、5％CO2细胞培养箱中培养48小时。
(6)每孔中加入20μl的5mg/ml MTT溶液，继续在培养箱中保温3～4小时。
(7)每孔加入100μl溶解液，继续在培养箱中保温过夜，使生成的甲臢晶体充分溶解。测定570nm光吸收值。
(8)根据光吸收值计算各样品浓度组的细胞生长抑制率。计算公式如下：
(1－实验孔平均光吸收值/对照孔平均光吸收值)×100％
3、实验结果
表1 不同浓度样品对8种细胞株的生长抑制率(％)
Figure PCTCN2015084297-appb-000001
表2 样品在体外对8种细胞株的IC50(μg/ml)
Figure PCTCN2015084297-appb-000002
4、结论
不同浓度的本发明薏苡仁油在体外对上述8种人肿瘤细胞株有不同程度的抑制作用。
通过试验证实，本发明所述的薏苡仁油及其制剂均能够达到上述试验例所述的效果。
本发明通过以下具体的实施例进一步说明本发明，但不作为本发明的限制。
具体实施方式
实施例1 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成20目，采用超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到40℃和45℃，保持一级解析釜和二级解析釜出口温度分别为50℃和35℃；液态CO2流量按所萃取薏苡仁粉末质量计，以2.5kg/h·kg的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力20Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力7Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为7Mpa和6Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2.5h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量55％的60℃石油醚，再根据酸值，加入油重45％的2％NaOH溶液，搅拌10min，静置20h后，除去下层皂脚，取上层用纯化水进行水洗，静置22h后，除去下层废水22h，除去下层废水，取上层进行第二次 水洗，静置46h后，除去下层废水；取上层加入油重80％丙酮破乳，静置3h后，除去下层废丙酮；取上层油溶液，加入5％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入4％经活化的高岭土，搅拌，在45℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加10％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经165℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得薏苡仁油，收率4.5％；测定其理化常数为：20℃时相对密度0.917，20℃时折光率1.471，酸值0.18，碘值102，皂化值190。
实施例2 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成30目，采用超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到35℃和40℃，保持一级解析釜和二级解析釜出口温度分别为20℃和15℃；液态CO2流量按所萃取薏苡仁粉末质量计，以7.5kg/h·kg的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力22Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力8Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为6Mpa和5Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量55％的90℃石油醚，再根据酸值，加入油重56％的2％NaOH溶液，搅拌10min后，静置22h后，除去下层皂脚，取上层用纯化水进行水洗，静置20h后，除去下层废水，取上层进行第二次水洗，静置48h后，除去下层废水；取上层加入油重90％丙酮破乳，静置2h后，除去下层废丙酮；取上层油溶液，加入8％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入6％经活化的高岭土，搅拌，在42℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置2h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加9％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经170℃减压干热灭菌1.5h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得薏苡仁油，收率4.9％；测定其理化常数为：20℃时相对密度0.920，20℃时折光率1.473，酸值0.19，碘值104，皂化值188。
实施例3 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成40目，采用超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到33℃和39℃，保持一级解析釜和二级解析釜出口温度分别为30℃和20℃；液态CO2流量按所萃取薏苡仁粉末质量计，以5.5kg/h·kg的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力19Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力9Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为5Mpa和4Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取3h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量55％的80℃石油醚，再根据酸值，加入油重36％的2％NaOH溶液，搅拌10min后，静置18h后，除去下层皂脚，取上层用纯化水进行水洗，静置18h后，除去下层废水，取上层进行第二次水洗，静置42h后，除去下层废水；取上层加入油重75％丙酮破乳，静置2h后，除去下层废丙酮；取上层油溶液，加入3％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入2％经活化的高岭土，搅拌，在47℃ 下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h，优选1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加11％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经160℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得薏苡仁油，收率4.7％；测定其理化常数为：20℃时相对密度0.918，20℃时折光率1.474，酸值0.15，碘值102，皂化值194。
实施例4 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成50目，采用超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到35℃和42℃，保持一级解析釜和二级解析釜出口温度分别为40℃和30℃；液态CO2流量按所萃取薏苡仁粉末质量计，以4.5kg/h·kg的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力21Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力10Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为7Mpa和5Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量55％的70℃石油醚，再根据酸值，加入油重50％的2％NaOH溶液，搅拌10min后，静置19h后，除去下层皂脚，取上层用纯化水进行水洗，静置21h后，除去下层废水，取上层进行第二次水洗，静置50h后，除去下层废水；取上层加入油重85％丙酮破乳，静置4h后，除去下层废丙酮；取上层油溶液，加入6％经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入5％经活化的高岭土，搅拌，在50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1.5h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加12％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经162℃减压干热灭菌1h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得薏苡仁油，收率4.0％；测定其理化常数为：20℃时相对密度0.920，20℃时折光率1.471，酸值0.16，碘值105，皂化值192。
实施例5 薏苡仁油的制备
超临界二氧化碳萃取：取薏苡仁粉碎成60目，采用超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到42℃和45℃，保持一级解析釜和二级解析釜出口温度分别为35℃和25℃；液态CO2流量按所萃取薏苡仁粉末质量计，以6.5kg/h·kg的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力23Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力8Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为6Mpa和4Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2.5h，得到薏苡仁油；
精制：取超临界CO2萃取得到的薏苡仁油，加入油重量55％的80℃石油醚，再根据酸值，加入油重40％的2％NaOH溶液，搅拌10min后，静置24h后，除去下层皂脚，取上层用纯化水进行水洗，静置24h后，除去下层废水，取上层进行第二次水洗，静置44h后，除去下层废水；取上层加入油重70％丙酮破乳，静置3h后，除去下层废丙酮；取上层油溶液，加入4％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入3％经活化的高岭土，搅拌，在40℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置2h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加8％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经165℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得薏苡仁油，收率4.3％； 测定其理化常数为：20℃时相对密度0.917，20℃时折光率1.473，酸值0.14，碘值103，皂化值192。
实施例6 三亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为12.6～14.2min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得三亚油酸甘油酯。
HR-EI-MS：m/z＝878.7344(Calcd.＝878.7363，C57H98O6)，不饱和度＝9。
IR(KBr film)：1746、1170、1098；2928、2856、724；3008、1655(弱)cm-1。
1H-NMR数据见表3。
13C-NMR数据见表4。
表3 实施例6-13所述化合物的1H-NMR图谱数据(CDCl3)
Figure PCTCN2015084297-appb-000003
其中，A：三亚油酸甘油酯，B：1-油酸-2,3-二亚油酸甘油酯，C：1-棕榈酸-2,3-二亚油酸甘油酯，D：1,3-二油酸-2-亚油酸甘油酯，E：1-棕榈酸-2-亚油酸-3-油酸甘油酯，F：1,3-二棕榈酸-2-亚油酸甘油三酯，G：三油酸甘油酯，H：1-棕榈酸-2,3-二油酸甘油酯。
表4 实施例6-13所述化合物的13H-NMR图谱数据(CDCl3)
Figure PCTCN2015084297-appb-000004
其中，A：三亚油酸甘油酯，B：1-油酸-2,3-二亚油酸甘油酯，C：1-棕榈酸-2,3-二亚油酸甘油酯，D：
1,3-二油酸-2-亚油酸甘油酯，E：1-棕榈酸-2-亚油酸-3-油酸甘油酯，F：1,3-二棕榈酸-2-亚油酸甘油三酯，G：三油酸甘油酯，H：1-棕榈酸-2,3-二油酸甘油酯。
实施例7 1-油酸-2,3-二亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为15.4～17.3min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-油酸-2,3-二亚油酸甘油酯。
HR-EI-MS：m/z＝880.7518(Calcd.＝880.7520，C55H98O6)，不饱和度＝7。
IR(KBr film)：1747，1164，1098；2925，2854，723；3008，1655(弱)cm-1。
1H-NMR数据见表3。
13C-NMR数据见表4。
实施例8 1-棕榈酸-2,3-二亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min，100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为17.4～18.1min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，得粗品。
二次纯化时流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，将上述粗品用流动相B配制成20mg/mL的溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(10 mm×250mm,5μm)；梯度条件：流动相B：0～23min：50％～60％，32～43min：60％～90％，43～60min：100％；流速：3mL/min；紫外检测波长：208nm，收集保留时间为31.2～34.7min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-棕榈酸-2,3-二亚油酸甘油酯单体。
HR-EI-MS：m/z＝854.7370(Calcd.＝854.7363,C55H98O6)，不饱和度＝7。
IR(KBr Flim)：＝1746，1165，1095；2926，2854，722；3009，1648(弱)cm-1。
1H-NMR数据见表3。
13C-NMR数据见表4。
实施例9 1,3-二油酸-2-亚油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为18.4～20.2min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-油酸-2,3-二亚油酸甘油酯。
HR-EI-MS：m/z＝882.7678(Calcd.＝882.7672,C57H102O6)，不饱和度＝7。
IR(KBr)：1747、1163、1097；2925、2855、723；3007、1655cm-1(弱)。
1H-NMR数据见表3。
13C-NMR数据见表4。
实施例10 1-棕榈酸-2-亚油酸-3-油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离。流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为20.3～21.4min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-棕榈酸-2-亚油酸-3-油酸甘油酯。
HR-EI-MS：m/z＝856.7519(Calcd.＝856.7513,C55H100O6)，不饱和度＝6。
IR(KBr)：1747、1164、1098；2925、2854、723；3008、1655cm-1(弱)。
1H-NMR数据见表3。
13C-NMR数据见表4。
实施例11 1,3-二棕榈酸-2-亚油酸甘油三酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为25.7～26.2min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1,3-二棕榈酸-2-亚油酸甘油三酯。
HR-EI-MS：m/z＝830.7371(Calcd.＝830.7363,C53H98O6)，不饱和度＝5。
IR(KBr film)：1747、1164、1098；2925、2854、723；3008、1655(弱)cm-1。
1H-NMR数据见表3。
13C-NMR数据见表4。
实施例12 三油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为26.6～27.7min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得三油酸甘油酯。
HR-EI-MS：m/z＝884.7851(Calcd.＝884.7833，C57H104O6)，不饱和度＝6。
IR(KBr film)：1749，1165，1095；2925，2854，723；3004，1654(弱)cm-1。
1H-NMR数据见表3。
13C-NMR数据见表4。
实施例13 1-棕榈酸-2,3-二油酸甘油酯的分离与鉴定
利用P3000A高效液相制备色谱仪进行初步分离，流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，用流动相B配制成50mg/mL的薏苡仁油溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(20mm×150mm，5μm)；梯度条件：流动相B：0～27min：50％～60％，27～35min：90％，35～45min：100％；流速：18mL/min；紫外检测波长：208nm；收集保留时间为28.2～29.3min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，得粗品。
二次纯化时流动相A：乙腈，流动相B：乙腈-四氢呋喃(1:1)，将上述粗品用流动相B配制成20mg/mL的溶液，每次分离进样体积1.5mL；色谱柱：Superstar BenetnachTM C18(10mm×250mm,5μm)；梯度条件：流动相B：0～23min：50％～60％，32～43min：60％～90％，43～60min：100％；流速：3mL/min；紫外检测波长：208nm，收集保留时间为32.9～35.1min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-棕榈酸-2,3-二油酸甘油酯。
HR-EI-MS：m/z＝858.7672(Calcd.＝858.7676，C55H102O6)，不饱和度＝5。
IR(KBr film)：1747，1166，1095；2926，2854，722；3003，1654(弱)cm-1。
1H-NMR数据见表3。
13C-NMR数据见表4。
实施例14 1,3-二棕榈酸-2-油酸甘油酯的制备
利用CHEETAH-HP100高效液相制备色谱仪进行初步分离，流动相为乙腈：四氢呋喃＝78:22，用四氢呋喃配制成750mg/mL的薏苡仁油溶液，每次分离进样体积2mL；色谱柱：Venusil XBP C18(2)(50*250mm，5μm
Figure PCTCN2015084297-appb-000005
)；流速：80mL/min；紫外检测波长：205nm/280nm；收集保留时间为29-38min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，得粗品。
二次纯化时流动相为乙腈：二氯甲烷＝65:35，将上述粗品用二氯甲烷配制成约10mg/mL的溶液，每次分离进样体积2mL；色谱柱：Venusil XBP C18(L)(30*150mm，5μm
Figure PCTCN2015084297-appb-000006
)；流速：32mL/min；紫外检测波长：205nm/280nm，收集保留时间为15min的色谱峰流分， 在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1,3-二棕榈酸-2-油酸甘油酯。
HR-EI-MS：m/z＝832.7542(Calcd.＝832.7566,C53H100O6)，不饱和度＝4。
IR(KBr film)：1747，1166，1095；2925，2854，722；3003，1654(弱)cm-1。
1H-NMR(CDCl3)数据见表5。
表5 实施例14所述化合物的1H-NMR图谱数据
位置 化学位移 H数目、峰形及耦合常数
H-C＝C 5.34 2H,m
CH-OCO 5.26 1H,m
-CH2-OCO 4.29 2H,dd,12.0,4.4
-CH2-OCO 4.14 2H,d,12.0,6.0
-CH2COO 2.31 2H,t,7.6
-CH2COO 2.31 4H,t,7.6
-CH2-CH＝ 2.00 4H,m
-CH2CH2COO 1.60 6H,m
-CH2 1.27 68H,m
-CH3 0.87 9H,t,6.8
13C-NMR(CDCl3)数据见表6。
表6 实施例14所述化合物的13H-NMR图谱数据
位置 化学位移 位置 化学位移
C1 1 173.282 C10 1 29.750～29.040
   2 172.839     2 129.999
   3 173.282     3 29.750～29.040
C2 1 34.026 C11 1 29.750～29.040
   2 34.179     2 27.205
   3 34.026     3 29.750～29.040
C3 1 24.848 C12 1 29.750～29.040
   2 24.848     2 29.750～29.040
   3 24.848     3 29.750～29.040
C4 1 29.750～29.040 C13 1 29.750～29.040
   2 29.750～29.040     2 29.750～29.040
   3 29.750～29.040     3 29.750～29.040
C5 1 29.750～29.040 C14 1 31.895
   2 29.750～29.040     2 29.750～29.040
   3 29.750～29.040     3 31.895
C6 1 29.750～29.040 C15 1 22.672
   2 29.750～29.040     2 29.750～29.040
   3 29.750～29.040     3 22.672
C7 1 29.750～29.040 C16 1 14.099
   2 29.750～29.040     2 31.895
   3 29.750～29.040     3 14.099
C8 1 29.750～29.040 C17 2 22.672
   2 27.159 C18 2 14.099
   3 29.750～29.040 CHO 68.852
C9 1 29.750～29.040 CH2O 62.076
   2 129.687    
   3 29.750～29.040    
实施例15 1,2-二油酸-3-硬脂酸甘油酯的制备
利用CHEETAH-HP100高效液相制备色谱仪进行初步分离，流动相为乙腈:四氢呋喃＝78:22，用四氢呋喃配制成750mg/mL的薏苡仁油溶液，每次分离进样体积2mL(1.5g)；色谱柱：Venusil XBP C18(2)(50*250mm，5μm
Figure PCTCN2015084297-appb-000007
)；流速：80mL/min；紫外检测波长：205nm/280nm；收集保留时间为29-38min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，得粗品。
二次纯化时流动相为乙腈：二氯甲烷＝65:35，将上述粗品用二氯甲烷配制成约10mg/mL的溶液，每次分离进样体积2mL；色谱柱：Venusil XBP C18(L)(30*150mm，5μm
Figure PCTCN2015084297-appb-000008
)；流速：32mL/min；紫外检测波长：205nm/280nm，收集保留时间为17min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1,2-二油酸-3-硬脂酸甘油酯。
HR-EI-MS：m/z＝886.8011(Calcd.＝886.7991,C57H106O6)，不饱和度＝5。
IR(KBr film)：1747，1166，1095；2926，2856，722；3003，1654(弱)cm-1。
1H-NMR(CDCl3)数据见表7。
表7 实施例15所述化合物的1H-NMR图谱
数据位置 化学位移 H数目、峰形及耦合常数
H-C＝C 5.35 4H,m
β-CH-OCO 5.26 1H,m
α-CH2-OCO 4.29 2H,dd,11.6,4.0
α-CH2-OCO 4.14 2H,d,12.0,6.0
-CH2COO 2.31 2H,t,7.6
-CH2COO 2.31 4H,t,7.6
-CH2-CH＝ 2.01 8H,m
-CH2CH2COO 1.60 6H,m
-CH2 1.27 74H,m
-CH3 0.87 9H,t,6.8
13C-NMR(CDCl3)数据见表8。
表8 实施例15所述化合物的13H-NMR图谱数据
位置 化学位移 位置 化学位移
C1 1 173.258 C10 1 129.999
   2 172.839     2 129.999
   3 173.282     3 29.00～30.00
C2 1 34.028 C11 1 27.206
   2 34.179     2 27.206
   3 34.028     3 29.00～30.00
C3 1 24.848 C12 1 29.00～30.00
   2 24.848     2 29.00～30.00
   3 24.848     3 29.00～30.00
C4 1 30.00～29.00 C13 1 29.00～30.00
   2 30.00～29.00     2 29.00～30.00
   3 30.00～29.00     3 29.00～30.00
C5 1 30.00～29.00 C14 1 29.00～30.00
   2 30.00～29.00     2 29.00～30.00
   3 30.00～29.00     3 31.895
C6 1 30.00～29.00 C15 1 29.00～30.00
   2 30.00～29.00     2 29.00～30.00
   3 30.00～29.00     3 22.672
C7 1 30.00～29.00 C16 1 31.895
   2 30.00～29.00     2 31.895
   3 30.00～29.00     3 31.895
C8 1 27.159 C17 1 22.672
   2 27.159     2 22.672
   3 29.00～30.00     3 22.672
C9 1 129.687 C18 1 14.099
   2 129.669     2 14.099
   3 29.00～30.00     3 14.099
    β‐CHO- 68.852
    α‐CH2O- 62.076
实施例16 1-油酸-2-亚油酸-3-硬脂酸甘油酯的制备
利用CHEETAH-HP100高效液相制备色谱仪进行初步分离，流动相为乙腈:四氢呋喃＝78:22，用四氢呋喃配制成750mg/mL的薏苡仁油溶液，每次分离进样体积2mL(1.5g)；色谱柱：Venusil XBP C18(2)(50*250mm，5μm
Figure PCTCN2015084297-appb-000009
)；流速：80mL/min；紫外检测波长：205nm/280nm；收集保留时间为29-38min的色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，得粗品。
二次纯化时流动相为乙腈：二氯甲烷＝65:35，将上述粗品用二氯甲烷配制成约10mg/mL的溶液，每次分离进样体积2mL；色谱柱：Venusil XBP C18(L)(30*150mm，5μm
Figure PCTCN2015084297-appb-000010
)；流速：32mL/min；紫外检测波长：205nm/280nm，收集保留时间19min色谱峰流分，在氮气的保护下采用旋转蒸发仪减压浓缩，用氯仿转移至10mL小瓶，在真空干燥箱中35℃干燥6h后，充入氮气，干燥好的样品于冰箱中冷冻保存，即得1-油酸-2-亚油酸-3-硬脂酸甘油酯。
HR-EI-MS：m/z＝884.7832(Calcd.＝884.7848,C57H104O6)，不饱和度＝6。
IR(KBr film)：1747、1164、1098；2925、2855、723；3008、1655cm-1(弱)。
1H-NMR(CDCl3)数据见表9。
表9 实施例16所述化合物的1H-NMR图谱数据
Figure PCTCN2015084297-appb-000011
13C-NMR(CDCl3)数据见表10。
表10 实施例16所述化合物的13H-NMR图谱数据
位置 化学位移 位置 化学位移
C1 1 173.25 C10 1 129.97
   2 172.83     2 128.08
   3 173.25     3 29.04～29.76
C2 1 34.03 C11 1 27.19
   2 34.18     2 25.62
   3 34.04     3 29.04～29.76
C3 1 24.86 C12 1 29.04～29.76
   2b 24.86     2 127.88
   3 24.86     3 29.04～29.76
C4 1 29.04～29.76 C13 1 29.04～29.76
   2b 29.04～29.76     2 130.22
   3 29.04～29.76     3 29.04～29.76
C5 1 29.04～29.76 C14 1 31.89
   2b 29.04～29.76     2 29.04～29.76
   3 29.04～29.76     3 31.89
C6 1 29.04～29.76 C15 1 22.67
   2b 29.04～29.76     2b 22.56
   3 29.04～29.76     3 22.67
C7 1 29.04～29.76 C16 1 31.91
   2b 29.04～29.76     2 31.52
   3 29.04～29.76     3 31.89
C8 1 29.04～29.76 C17 1 22.67
   2 27.19     2 22.56
   3 29.04～29.76     3 22.67
C9 1 129.70 C18 1 14.09
   2 130.01     2 14.05
   3 29.04～29.76     3 14.09
    CH-O 68.89
    2CH2-O 62.08
实施例17 本发明薏苡仁油注射液的制备
处方：
Figure PCTCN2015084297-appb-000012
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.10％
1-油酸-2,3-二亚油酸甘油酯16.18％
1-棕榈酸-2,3-二亚油酸甘油酯6.56％
1,3-二油酸-2-亚油酸甘油酯16.69％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.96％
1,3-二棕榈酸-2-亚油酸甘油三酯2.88％
三油酸甘油酯18.30％
1-棕榈酸-2,3-二油酸甘油酯10.18％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.72％
1,3-二棕榈酸-2-油酸甘油酯1.88％
1,2-二油酸-3-硬脂酸甘油酯1.60％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油脂与水相分别加热至60℃后，置高压均质机进行高压乳化，乳化时均质机低压为6MPa，高压为30MPa，再循环均质4遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至8.5；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例18 本发明薏苡仁油注射液的制备
处方：
Figure PCTCN2015084297-appb-000013
Figure PCTCN2015084297-appb-000014
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯4.87％
1-油酸-2,3-二亚油酸甘油酯13.00％
1-棕榈酸-2,3-二亚油酸甘油酯5.25％
1,3-二油酸-2-亚油酸甘油酯15.13％
1-棕榈酸-2-亚油酸-3-油酸甘油酯10.26％
1,3-二棕榈酸-2-亚油酸甘油三酯3.05％
三油酸甘油酯20.46％
1-棕榈酸-2,3-二油酸甘油酯11.50％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.95％
1,3-二棕榈酸-2-油酸甘油酯2.16％
1,2-二油酸-3-硬脂酸甘油酯1.84％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油酯与水相分别加热至70℃后，置高压均质机进行高压乳化，乳化时均质机低压为12MPa，高压为45MPa，再循环均质3遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至7.1；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例19 本发明薏苡仁油注射液的制备
处方：
Figure PCTCN2015084297-appb-000015
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯5.47％
1-油酸-2,3-二亚油酸甘油酯14.75％
1-棕榈酸-2,3-二亚油酸甘油酯6.01％
1,3-二油酸-2-亚油酸甘油酯18.19％
1-棕榈酸-2-亚油酸-3-油酸甘油酯14.11％
1,3-二棕榈酸-2-亚油酸甘油三酯2.60％
三油酸甘油酯16.25％
1-棕榈酸-2,3-二油酸甘油酯9.11％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.88％
1,3-二棕榈酸-2-油酸甘油酯2.09％
1,2-二油酸-3-硬脂酸甘油酯1.76％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油酯与水相分别加热至65℃后，置高压均质机进行高压乳化，乳化时均质机低压为10MPa，高压为30MPa，再循环均质5遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至4.8；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例20 本发明薏苡仁油注射液的制备
处方：
Figure PCTCN2015084297-appb-000016
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯5.96％
1-油酸-2,3-二亚油酸甘油酯15.93％
1-棕榈酸-2,3-二亚油酸甘油酯6.43％
1,3-二油酸-2-亚油酸甘油酯16.20％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.57％
1,3-二棕榈酸-2-亚油酸甘油三酯2.79％
三油酸甘油酯17.69％
1-棕榈酸-2,3-二油酸甘油酯9.87％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.75％
1,3-二棕榈酸-2-油酸甘油酯1.92％
1,2-二油酸-3-硬脂酸甘油酯1.66％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油酯与水相分别加热至68℃后，置高压均质机进行高压乳化，乳化时均质机低压为7MPa，高压为35MPa，再循环均质3遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至6.8；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例21 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 200g
维生素E  0.20g
制成  1000粒
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.20％
1-油酸-2,3-二亚油酸甘油酯16.58％
1-棕榈酸-2,3-二亚油酸甘油酯6.69％
1,3-二油酸-2-亚油酸甘油酯16.87％
1-棕榈酸-2-亚油酸-3-油酸甘油酯13.09％
1,3-二棕榈酸-2-亚油酸甘油三酯2.91％
三油酸甘油酯18.42％
1-棕榈酸-2,3-二油酸甘油酯10.27％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.67％
1,3-二棕榈酸-2-油酸甘油酯1.86％
1,2-二油酸-3-硬脂酸甘油酯1.56％
工艺：
胶液配制：按重量比为1：1.2：0.8：0.01称取适量明胶、纯化水、甘油和10％羟苯乙酯溶液；依次将甘油、纯化水、10％羟苯乙酯溶液加入化胶罐内，加热至70℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在60℃下存放，备用；
药液配制：将配方量的薏苡仁油、维生素E加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在18℃、相对湿度<35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得。
实施例22 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 800g
吐温80 0.60g
制成 1000粒
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.69％
1-油酸-2,3-二亚油酸甘油酯17.88％
1-棕榈酸-2,3-二亚油酸甘油酯7.21％
1,3-二油酸-2-亚油酸甘油酯14.92％
1-棕榈酸-2-亚油酸-3-油酸甘油酯11.55％
1,3-二棕榈酸-2-亚油酸甘油三酯3.14％
三油酸甘油酯19.86％
1-棕榈酸-2,3-二油酸甘油酯11.08％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.50％
1,3-二棕榈酸-2-油酸甘油酯1.70％
1,2-二油酸-3-硬脂酸甘油酯1.43％
工艺：
胶液配制：按重量比为1：1.2：0.8：0.01称取适量明胶、纯化水、甘油和苯甲酸；依次将甘油、纯化水、苯甲酸加入化胶罐内，加热至90℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在56℃下存放，备用；
药液配制：将配方量的薏苡仁油、吐温80加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在26℃、相对湿度<35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得。
实施例23 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 500g
维生素E  0.40g
制成  1000粒
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.99％
1-油酸-2,3-二亚油酸甘油酯18.69％
1-棕榈酸-2,3-二亚油酸甘油酯7.54％
1,3-二油酸-2-亚油酸甘油酯19.02％
1-棕榈酸-2-亚油酸-3-油酸甘油酯14.75％
1,3-二棕榈酸-2-亚油酸甘油三酯3.28％
三油酸甘油酯15.96％
1-棕榈酸-2,3-二油酸甘油酯8.11％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.38％
1,3-二棕榈酸-2-油酸甘油酯1.52％
1,2-二油酸-3-硬脂酸甘油酯1.29％
工艺：
胶液配制：按重量比为1：0.9：0.6：0.005称取适量明胶、纯化水、甘油和山梨酸钾；依次将甘油、纯化水、山梨酸钾加入化胶罐内，加热至80℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在62℃下存放，备用；
药液配制：将配方量的薏苡仁油、维生素E加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在28℃、相对湿度<35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得。
实施例24 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 600g
吐温80 0.3g
制成 1000粒
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.15％
1-油酸-2,3-二亚油酸甘油酯16.31％
1-棕榈酸-2,3-二亚油酸甘油酯6.66％
1,3-二油酸-2-亚油酸甘油酯16.77％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.89％
1,3-二棕榈酸-2-亚油酸甘油三酯2.88％
三油酸甘油酯18.30％
1-棕榈酸-2,3-二油酸甘油酯10.18％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.81％
1,3-二棕榈酸-2-油酸甘油酯2.08％
1,2-二油酸-3-硬脂酸甘油酯1.81％
工艺：
胶液配制：按重量比为1：1.0：0.5：0.008称取适量明胶、纯化水、甘油和醋酸氯己定；依次将甘油、纯化水、醋酸氯己定加入化胶罐内，加热至85℃后，再加入明胶不断搅拌、 抽真空，直至明胶完全溶解，将胶液过滤，在56℃下存放，备用；
药液配制：将配方量的薏苡仁油、吐温80加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在30℃、相对湿度<35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得。
实施例25 本发明薏苡仁油注射液的制备
处方：
Figure PCTCN2015084297-appb-000017
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯5.13％
1-油酸-2,3-二亚油酸甘油酯14.09％
1-棕榈酸-2,3-二亚油酸甘油酯5.74％
1,3-二油酸-2-亚油酸甘油酯18.61％
1-棕榈酸-2-亚油酸-3-油酸甘油酯11.90％
1,3-二棕榈酸-2-亚油酸甘油三酯2.88％
三油酸甘油酯20.75％
1-棕榈酸-2,3-二油酸甘油酯11.19％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.92％
1,3-二棕榈酸-2-油酸甘油酯2.11％
1,2-二油酸-3-硬脂酸甘油酯1.84％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油与水相分别加热至60℃后，置高压均质机进行高压乳化，乳化时均质机低压为7MPa，高压为26MPa，再循环均质5遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至6.8；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例26 本发明薏苡仁油注射液的制备
处方：
Figure PCTCN2015084297-appb-000018
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯5.71％
1-油酸-2,3-二亚油酸甘油酯15.11％
1-棕榈酸-2,3-二亚油酸甘油酯6.02％
1,3-二油酸-2-亚油酸甘油酯15.45％
1-棕榈酸-2-亚油酸-3-油酸甘油酯14.20％
1,3-二棕榈酸-2-亚油酸甘油三酯3.20％
三油酸甘油酯19.91％
1-棕榈酸-2,3-二油酸甘油酯9.22％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.78％
1,3-二棕榈酸-2-油酸甘油酯2.01％
1,2-二油酸-3-硬脂酸甘油酯1.70％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油与水相分别加热至70℃后，置高压均质机进行高压乳化，乳化时均质机低压为11MPa，高压为48MPa，再循环均质6遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至7.5；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例27 本发明薏苡仁油注射液的制备
处方：
Figure PCTCN2015084297-appb-000019
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.18％
1-油酸-2,3-二亚油酸甘油酯16.03％
1-棕榈酸-2,3-二亚油酸甘油酯6.51％
1,3-二油酸-2-亚油酸甘油酯16.30％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.83％
1,3-二棕榈酸-2-亚油酸甘油三酯2.81％
三油酸甘油酯18.10％
1-棕榈酸-2,3-二油酸甘油酯9.95％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.71％
1,3-二棕榈酸-2-油酸甘油酯1.97％
1,2-二油酸-3-硬脂酸甘油酯1.69％
工艺：
称取处方配制量的注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油，并加注射用水至规定量，搅拌均匀备用；
另称取薏苡仁油，将称取的油与水相分别加热至65℃后，置高压均质机进行高压乳化，乳化时均质机低压为8MPa，高压为40MPa，再循环均质4遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至6.5；
将制得均匀乳剂氮气加压通过≤3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷却即得。
实施例28 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 200g
维生素E  0.20g
制成 1000粒
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.51％
1-油酸-2,3-二亚油酸甘油酯17.26％
1-棕榈酸-2,3-二亚油酸甘油酯6.84％
1,3-二油酸-2-亚油酸甘油酯17.65％
1-棕榈酸-2-亚油酸-3-油酸甘油酯13.56％
1,3-二棕榈酸-2-亚油酸甘油三酯3.07％
三油酸甘油酯19.33％
1-棕榈酸-2,3-二油酸甘油酯8.69％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.59％
1,3-二棕榈酸-2-油酸甘油酯1.73％
1,2-二油酸-3-硬脂酸甘油酯1.49％
工艺：
胶液配制：按重量比为1：1.2：0.8：0.01称取适量明胶、纯化水、甘油和10％羟苯乙酯溶液；依次将甘油、纯化水、10％羟苯乙酯溶液加入化胶罐内，加热至70℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在59℃下存放，备用；
药液配制：将配方量的薏苡仁油、维生素E加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在16℃、相对湿度<35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得。
实施例29 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 800g
吐温80 0.60g
制成 1000粒
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.71％
1-油酸-2,3-二亚油酸甘油酯18.01％
1-棕榈酸-2,3-二亚油酸甘油酯7.25％
1,3-二油酸-2-亚油酸甘油酯18.50％
1-棕榈酸-2-亚油酸-3-油酸甘油酯10.95％
1,3-二棕榈酸-2-亚油酸甘油三酯2.63％
三油酸甘油酯17.14％
1-棕榈酸-2,3-二油酸甘油酯9.78％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.42％
1,3-二棕榈酸-2-油酸甘油酯1.60％
1,2-二油酸-3-硬脂酸甘油酯1.31％
工艺：
胶液配制：按重量比为1：1.2：0.8：0.01称取适量明胶、纯化水、甘油和苯甲酸；依 次将甘油、纯化水、苯甲酸加入化胶罐内，加热至90℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在60℃下存放，备用；
药液配制：将配方量的薏苡仁油、吐温80加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在26℃、相对湿度<35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得。
实施例30 本发明薏苡仁油胶囊剂的制备
处方：
薏苡仁油 500g
维生素E  0.40g
制成 1000粒
其中，薏苡仁油含有以下甘油三酯成分：
三亚油酸甘油酯6.85％
1-油酸-2,3-二亚油酸甘油酯18.24％
1-棕榈酸-2,3-二亚油酸甘油酯7.25％
1,3-二油酸-2-亚油酸甘油酯15.01％
1-棕榈酸-2-亚油酸-3-油酸甘油酯12.03％
1,3-二棕榈酸-2-亚油酸甘油三酯3.01％
三油酸甘油酯18.60％
1-棕榈酸-2,3-二油酸甘油酯10.80％
1-油酸-2-亚油酸-3-硬脂酸甘油酯1.39％
1,3-二棕榈酸-2-油酸甘油酯1.53％
1,2-二油酸-3-硬脂酸甘油酯1.30％
工艺：
胶液配制：按重量比为1：0.9：0.6：0.005称取适量明胶、纯化水、甘油和山梨酸钾；依次将甘油、纯化水、山梨酸钾加入化胶罐内，加热至80℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在62℃下存放，备用；
药液配制：将配方量的薏苡仁油、维生素E加入配料罐内，不断搅拌，直至混合均匀；
压胶囊：根据胶囊大小选择合适的压丸模具，在20℃、相对湿度<35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得。

Claims (10)

  1. 一种薏苡仁油，其特征在于：该薏苡仁油中含有如下质量百分含量的11种甘油三酯类成分：三亚油酸甘油酯4.87～6.99％、1-油酸-2,3-二亚油酸甘油酯13.00～18.69％、1-棕榈酸-2,3-二亚油酸甘油酯5.25～7.54％、1,3-二油酸-2-亚油酸甘油酯13.23～19.02％、1-棕榈酸-2-亚油酸-3-油酸甘油酯10.26～14.75％、1,3-二棕榈酸-2-亚油酸甘油三酯2.28～3.28％、三油酸甘油酯14.44～20.76％、1-棕榈酸-2,3-二油酸甘油酯8.06～11.58％、1-油酸-2-亚油酸-3-硬脂酸甘油酯1.37～1.97％、1,3-二棕榈酸-2-油酸甘油酯1.52～2.19％和1,2-二油酸-3-硬脂酸甘油酯1.29～1.86％。
  2. 根据权利要求1所述的薏苡仁油，其特征在于：所述薏苡仁油按脂肪油检测理化常数为：20℃时相对密度0.917～0.920，20℃时折光率1.471～1.474，酸值<0.2，碘值102～106，皂化值188～195；所述甘油三酯成分的质量百分含量为：三亚油酸甘油酯5.47～6.69％、1-油酸-2,3-二亚油酸甘油酯14.63～17.88％、1-棕榈酸-2,3-二亚油酸甘油酯5.9～7.21％、1,3-二油酸-2-亚油酸甘油酯14.88～18.19％、1-棕榈酸-2-亚油酸-3-油酸甘油酯11.55～14.11％、1,3-二棕榈酸-2-亚油酸甘油三酯2.57～3.14％、三油酸甘油酯16.25～19.86％、1-棕榈酸-2,3-二油酸甘油酯9.07～11.08％、1-油酸-2-亚油酸-3-硬脂酸甘油酯1.54～1.88％、1,3-二棕榈酸-2-油酸甘油酯1.71～2.09％和1,2-二油酸-3-硬脂酸甘油酯1.45～1.78％；
    优选地，所述甘油三酯成分的质量百分含量为：三亚油酸甘油酯5.96～6.20％、1-油酸-2,3-二亚油酸甘油酯15.93～16.58％、1-棕榈酸-2,3-二亚油酸甘油酯6.43～6.69％、1,3-二油酸-2-亚油酸甘油酯16.20～16.87％、1-棕榈酸-2-亚油酸-3-油酸甘油酯12.57～13.09％、1,3-二棕榈酸-2-亚油酸甘油三酯2.79～2.91％、三油酸甘油酯17.69～18.42％、1-棕榈酸-2,3-二油酸甘油酯9.87～10.27％、1-油酸-2-亚油酸-3-硬脂酸甘油酯1.68～1.74％、1,3-二棕榈酸-2-油酸甘油酯1.86～1.94％和1,2-二油酸-3-硬脂酸甘油酯1.58～1.65％。
  3. 一种权利要求1所述薏苡仁油的制备方法，具体包括如下步骤：
    超临界二氧化碳萃取：取薏苡仁粉碎成20目～60目，采用超临界CO2萃取器萃取，将薏苡仁粉装入萃取釜，用夹套循环热水加热CO2预热器、萃取釜和分离柱，使萃取温度和分离温度分别达到33～45℃和30～45℃，保持一级解析釜和二级解析釜出口温度分别为20～50℃和15～35℃；液态CO2流量按所萃取薏苡仁粉末质量计，以2.5kg/h·kg～7.5kg/h·kg的流量经高压泵加压进入CO2预热器，成为超临界状态下的流体，进入萃取釜，保持压力19～23Mpa，萃取薏苡仁油；溶有薏苡仁油的CO2流体进入分离柱，控制分离柱压力7～10Mpa，分离得到薏苡仁油；从分离柱出来的CO2气体先后进入一级、二级解析釜，分别保持压力为5～7Mpa和4～6Mpa，弃去解析得到的水分等杂质，CO2气体经冷凝器变成液态CO2，循环使用，连续萃取2～3h，得到薏苡仁油；
    精制：取超临界CO2萃取得到的薏苡仁油，加入油重量55％的60℃～90℃石油醚，再根据酸值，加入油重36％～56％的2％NaOH溶液，搅拌10min后，静置18～24h后，除去下层皂脚，取上层用纯化水进行水洗，静置18～24h后，除去下层废水，取上层进行第二次水洗，静置40～50h后，除去下层废水；取上层加入油重70％～90％丙酮破乳，静置2～4h后，除去下层废丙酮；取上层油溶液，加入3％～8％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入2％～6％经活化的高岭土，搅拌，在40～50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1～2h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加8％～12％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经160～170℃减压干热灭菌1～2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得；
    优选地，所述精制步骤为：
    取超临界CO2萃取得到的薏苡仁油，加入油重量55％的60℃～90℃石油醚，再根据酸值，加入油重36％～56％的2％NaOH溶液，搅拌10min后，静置20h后，除去下层皂脚，取上层用纯化水进行水洗，静置22h后，除去下层废水，取上层进行第二次水洗，静置46h后，除去下层废水；取上层加入油重70％～90％丙酮破乳，静置3h后，除去下层废丙酮；取上层油溶液，加入5％的经活化的中性氧化铝，搅拌30min后，过滤；滤液加热后，加入4％经活化的高岭土，搅拌，在40～50℃下保温30min，过滤；滤液减压回收溶剂后，再加纯化水进行水洗，静置1h后，除去下层废水；上层油在充氮条件下，加热减压干燥，再加10％经活化的中性氧化铝，搅拌，置冷处静置，过滤，过滤后的油再经160～170℃减压干热灭菌2h，冷却后经0.2μm微孔滤膜过滤，分装于500ml玻璃输液瓶中，密封，即得。
  4. 一种药物制剂，其特征在于含有治疗有效量的权利要求1～3任一所述的薏苡仁油及一种或几种药学上可接受的载体，其中所述药学上可接受的载体包括药学领域常规的稀释剂、赋形剂、填充剂、乳化剂、粘合剂、润滑剂、吸收促进剂、表面活性剂、崩解剂、润滑剂或抗氧化剂，必要时还可以加入香味剂、甜味剂、防腐剂或着色剂；
    其中，所述药学上可接受的载体可以选自：甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、大豆磷脂、维生素C、维生素E、EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、羟苯乙酯溶液、苯甲酸、山梨酸钾、醋酸氯己定、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙或硬脂酸镁。
  5. 根据权利要求4所述药物制剂，其可以是口服固体制剂、口服液体制剂或注射剂；
    其中，
    所述口服固体制剂选自胶囊剂、片剂、滴丸、颗粒剂、浓缩丸中的任何一种；
    所述口服液体制剂选自水性或油性悬浮液、溶液、乳剂、糖浆剂或酏剂，或是一种在使用前可用水或其它适宜的载体复配的干燥产品；
    所述注射剂选自纳米混悬剂、脂质体、乳剂、冻干粉针剂和水针剂中的任何一种。
  6. 根据权利要求5所述药物制剂，其特征在于所述注射剂包含如下成分：
    薏苡仁油 50～350g
    注射用大豆磷脂或可供注射用大豆磷脂 10～40g
    注射用甘油或可供注射用甘油 15～50g
    注射用水加至 1000ml。
  7. 根据权利要求6所述药物制剂的制备方法，其特征在于包括如下步骤：
    称取处方配制量的注射用大豆磷脂或可供注射用大豆磷脂，加适量的注射用水后，用高剪切分散乳化机分散至无块状及颗粒状固体，加入按配方量称取的注射用甘油或可供注射用甘油，并加注射用水至规定量，搅拌均匀备用；
    另称取薏苡仁油，将称取的油酯与水相分别加热至60～70℃后，置高压均质机进行高压乳化，乳化时均质机低压为5～12MPa，高压为25～50MPa，再循环均质3～6遍，至2μm以下颗粒应不少于95％，5μm以上颗粒不得检出，必要时用NaOH或HCl调节pH至4.8～8.5，优选6.8～7，最优选为6.8；
    将制得均匀乳剂氮气加压通过小于等于3μm的微孔滤芯过滤器过滤，充氮灌装灭菌，冷 却即得。
  8. 根据权利要求5所述药物制剂，其特征在于所述胶囊剂包含如下成分：
    薏苡仁油 200～800g
    抗氧化剂和/或乳化剂 0.20～0.60g
    制成 1000粒。
  9. 根据权利要求8所述药物制剂的制备方法，其特征在于包括如下步骤：
    胶液配制：按重量比为1∶0.6～1.2∶0.3～0.8∶0.0001～0.01称取适量明胶、纯化水、甘油和防腐剂；依次将甘油、纯化水、防腐剂加入化胶罐内，加热至70℃～90℃后，再加入明胶不断搅拌、抽真空，直至明胶完全溶解，将胶液过滤，在56～62℃下存放，备用；
    药液配制：将配方量的薏苡仁油、抗氧化剂和/或乳化剂加入配料罐内，不断搅拌，直至混合均匀；
    压胶囊：根据胶囊大小选择合适的压丸模具，在15～30℃、相对湿度小于35％条件下进行压丸定型后干燥，剔除大小丸，再用95％药用乙醇洗丸后，继续干燥至含水量小于12％，目检剔除不合格胶囊，包装即得；
    其中，
    所述防腐剂选自10％羟苯乙酯溶液、苯甲酸、山梨酸钾和醋酸氯己定中的一种；
    所述抗氧化剂为维生素E，乳化剂为吐温80。
  10. 根据权利要求1所述薏苡仁油在制备抗肿瘤药物中的应用：
    其中，所述肿瘤是指早期、中期或晚期的肺癌、肝癌、胰腺癌、前列腺癌、卵巢癌或乳腺癌。
PCT/CN2015/084297 2014-07-18 2015-07-17 含有11种甘油三酯的薏苡仁油、制剂及其应用 Ceased WO2016008442A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2015291531A AU2015291531B2 (en) 2014-07-18 2015-07-17 Coix seed oil containing 11 triglycerides, and pharmaceutical preparation and use thereof
NZ726575A NZ726575A (en) 2014-07-18 2015-07-17 Coix seed oil containing 11 triglycerides, and pharmaceutical preparation and use thereof
US15/324,873 US10314878B2 (en) 2014-07-18 2015-07-17 Coix seed oil containing 11 triglycerides, and pharmaceutical preparation and use thereof
EA201790119A EA033647B1 (ru) 2014-07-18 2015-07-17 Масло семян коикса, содержащее 11 триглицеридов, и его фармацевтический препарат и его применение
CN201580016352.9A CN106413702B (zh) 2014-07-18 2015-07-17 含有11种甘油三酯的薏苡仁油、制剂及其应用
CA2954796A CA2954796C (en) 2014-07-18 2015-07-17 Coix seed oil comprising 11 triglycerides, formulation and application thereof
JP2017522710A JP6473811B2 (ja) 2014-07-18 2015-07-17 １１種のトリグリセリド含むヨクイニン油、製剤及びその応用
SG11201700123UA SG11201700123UA (en) 2014-07-18 2015-07-17 Coix seed oil comprising 11 triglycerides, formulation and application thereof
EP15821404.9A EP3170496A4 (en) 2014-07-18 2015-07-17 Coix seed oil comprising 11 triglycerides, formulation and application thereof
KR1020177001432A KR101919386B1 (ko) 2014-07-18 2015-07-17 11가지 트리글리세라이드를 포함한 의이인오일, 제제 및 그 응용
AP2017009707A AP2017009707A0 (en) 2014-07-18 2015-07-17 Coix seed oil comprising 11 triglycerides, formulation and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410343083.4A CN105250804A (zh) 2014-07-18 2014-07-18 含有11种甘油三酯的薏苡仁油、制剂及其应用
CN201410343083.4 2014-07-18

Publications (1)

Publication Number Publication Date
WO2016008442A1 true WO2016008442A1 (zh) 2016-01-21

Family

ID=55077928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/084297 Ceased WO2016008442A1 (zh) 2014-07-18 2015-07-17 含有11种甘油三酯的薏苡仁油、制剂及其应用

Country Status (12)

Country Link
US (1) US10314878B2 (zh)
EP (1) EP3170496A4 (zh)
JP (1) JP6473811B2 (zh)
KR (1) KR101919386B1 (zh)
CN (2) CN105250804A (zh)
AP (1) AP2017009707A0 (zh)
AU (1) AU2015291531B2 (zh)
CA (1) CA2954796C (zh)
EA (1) EA033647B1 (zh)
NZ (1) NZ726575A (zh)
SG (1) SG11201700123UA (zh)
WO (1) WO2016008442A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432004A (zh) * 2018-12-26 2019-03-08 江苏盈科生物制药有限公司 一种脂肪乳注射液的制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110835523B (zh) * 2018-08-17 2022-02-15 中国石油化工股份有限公司 一种用于稠油冷采的乳化降粘剂及其制备方法
CN109576051A (zh) * 2018-12-06 2019-04-05 江西省药明扬海医药科技有限公司 一种氧化铝废渣中薏苡仁油的提取方法
KR102555338B1 (ko) * 2020-09-11 2023-07-13 에스에스바이오팜 주식회사 호박씨 오일을 함유하는 식품 조성물.
CN112538017B (zh) * 2020-12-15 2022-09-09 浙江工商大学 一种提取制备薏苡仁外皮抗氧化活性酚酸成分的方法
CN118453714A (zh) * 2024-05-23 2024-08-09 上海市第八人民医院 药物组合物及其在制备用于抑制耐甲氧西林金黄色葡萄球菌的药物上的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1080176A (zh) * 1993-01-01 1994-01-05 浙江省中医院 薏苡仁中性油脂乳剂
CN1485418A (zh) * 2002-09-28 2004-03-31 李大鹏 超临界二氧化碳提取薏苡仁粗油方法
CN1485072A (zh) * 2002-09-28 2004-03-31 治疗前列腺疾病的薏苡仁油软胶囊及其应用
CN104173824A (zh) * 2014-07-18 2014-12-03 浙江康莱特集团有限公司 含有8种甘油三酯的薏苡仁油、制剂及其应用
US20140370129A1 (en) * 2013-06-14 2014-12-18 Zhejiang Kanglaite Group Co., Ltd. Dosing regimen and method for treating cancer using a coix seed oil emulsion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30249A (en) * 1992-09-16 1997-02-05 Zhejiang Provincial Hospital O Neutral lipids from endosperm of job's tears
CN1029662C (zh) * 1992-09-17 1995-09-06 李大鹏 薏苡仁中性油脂及其提取方法
JP2002212586A (ja) * 2001-01-19 2002-07-31 Kanegafuchi Chem Ind Co Ltd 油脂の精製方法
CN1234828C (zh) * 2002-11-21 2006-01-04 上海高科联合生物技术研发有限公司 超临界二氧化碳萃取薏苡仁油的方法
CN1778380A (zh) * 2004-11-23 2006-05-31 乔志亚生技股份有限公司 薏仁油萃取的方法及组成分及其疗效
CN101036761B (zh) * 2007-04-23 2010-05-19 肖志勇 一种薏苡仁油的制备方法
CN101940738A (zh) * 2010-07-27 2011-01-12 辽宁中医药大学 薏苡仁抗癌中药及其制备方法
CN102177978B (zh) * 2011-04-14 2013-01-30 西南大学 薏苡仁米糠及其运用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1080176A (zh) * 1993-01-01 1994-01-05 浙江省中医院 薏苡仁中性油脂乳剂
CN1485418A (zh) * 2002-09-28 2004-03-31 李大鹏 超临界二氧化碳提取薏苡仁粗油方法
CN1485072A (zh) * 2002-09-28 2004-03-31 治疗前列腺疾病的薏苡仁油软胶囊及其应用
US20140370129A1 (en) * 2013-06-14 2014-12-18 Zhejiang Kanglaite Group Co., Ltd. Dosing regimen and method for treating cancer using a coix seed oil emulsion
CN104173824A (zh) * 2014-07-18 2014-12-03 浙江康莱特集团有限公司 含有8种甘油三酯的薏苡仁油、制剂及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of EP3170496A4 *
XIANG, ZHIMIN ET AL., IDENTIFICATION OF TRIACYLGLYCEROLS IN COIX OIL BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-ATMOSPHERIC PRESSURE CHEMICAL IONIZATION-MASS SPECTROMETRY, China, XP008183620 *
XIANG, ZHIMIN ET AL.: "Identification of Triacylglycerols in Coix Oil by High Performance Liquid Chromatography-Atmospheric Pressure Chemical Ionization-Mass Spectrometry", CHINA JOURNAL OF CHINESE MATERIA MEDICA, vol. 33, no. 18, 30 September 2005 (2005-09-30), pages 1436 - 1438, XP008183620 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432004A (zh) * 2018-12-26 2019-03-08 江苏盈科生物制药有限公司 一种脂肪乳注射液的制备方法

Also Published As

Publication number Publication date
US10314878B2 (en) 2019-06-11
CN105250804A (zh) 2016-01-20
EA033647B1 (ru) 2019-11-13
EP3170496A4 (en) 2018-03-28
EP3170496A1 (en) 2017-05-24
SG11201700123UA (en) 2017-03-30
NZ726575A (en) 2018-01-26
CN106413702B (zh) 2017-09-12
AU2015291531B2 (en) 2018-03-29
CN106413702A (zh) 2017-02-15
US20170209517A1 (en) 2017-07-27
CA2954796A1 (en) 2016-01-21
KR101919386B1 (ko) 2018-11-16
CA2954796C (en) 2019-10-29
EA201790119A1 (ru) 2017-07-31
JP2017522441A (ja) 2017-08-10
JP6473811B2 (ja) 2019-02-20
KR20170019448A (ko) 2017-02-21
AP2017009707A0 (en) 2017-01-31
AU2015291531A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
US9855310B2 (en) Coix seed oil containing 8 triglycerides, and pharmaceutical preparation and use thereof
WO2016008442A1 (zh) 含有11种甘油三酯的薏苡仁油、制剂及其应用
CN106470680B (zh) 含有16种甘油酯的薏苡仁油、制剂及其应用
US9585929B2 (en) Coix seed oil containing 13 glycerides, and pharmaceutical preparation and use thereof
CN105254498B (zh) 化合物1,3‑二油酸‑2‑亚油酸甘油酯、制剂、制备方法及其应用
WO2016008437A1 (zh) 化合物1-棕榈酸-2-亚油酸-3-油酸甘油酯、制剂、制备方法及其应用
WO2016008441A1 (zh) 含有13种甘油酯的药物组合物、制剂及其应用
CN105267776B (zh) 含有13种甘油酯的薏苡仁油、制剂及其应用
HK1236404A1 (zh) 含有13种甘油酯的薏苡仁油、制剂及其应用
HK1236404B (zh) 含有13种甘油酯的薏苡仁油、制剂及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15821404

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015291531

Country of ref document: AU

Date of ref document: 20150717

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015821404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015821404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15324873

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2954796

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017522710

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177001432

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201790119

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2954796

Country of ref document: CA